Formulari Ubat ubatan kkm

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Antiretroviral combination therapy of HIV infection in1 Abacavir Sulphate 600 mg J05AR02964T1001X A* adults and adolescents from ADULTS & ADOLESCENT (> and Lamivudine 300 mg X 12 years of age with the 12 years of age): Tablet following criteria: Recommended dose is one i) Patients unsuitable or failed tablet once daily. Not to be other HAART treatment used in adults or adolescents ii) Patients who are at high weigh less than 40kg. risk of renal impairment CHILDREN : Not iii) Patients with osteoporosis recommended or at high risk of bone loss Only for treatment of: i) Non insulin dependent diabetes mellitus (NIDDM) when diet therapy is2 Acarbose 50 mg Tablet A10BF01000T1001X A/KK insufficient. Initially 50 mg daily, increase X ii) Non insulin dependent to 3 times daily up to 100 mg diabetes mellitus (NIDDM) in 3 times daily. Max 200 mg 3 combination with existing times daily conventional oral therapy where glycaemic control is inadequate Reduction of intraocular pressure in open-angle3 Acetazolamide 250 mg S01EC01000T1001X B glaucoma, secondary 250mg 1-4 times a day, the Tablet X glaucoma and peri- dosage being titrated operatively in angle-closure according to patient response glaucoma Reduction of intra-ocular pressure in open-angle Adult : 250-1000mg per4 Acetazolamide 500 mg S01EC01000P4001X B glaucoma, secondary 24hours, usually in divided Injection X glaucoma and peri- doses for amounts over operatively in angle-closure 250mg daily glaucoma Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg Acetylcysteine 200 mg/ml IV in 200 ml over 60 minutes, Injection V03AB23520P3001X Antidote for paracetamol then 50 mg/kg IV in 500 ml5 X A* poisoning over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour Prevention of myocardial6 Acetylsalicylic Acid 100 mg, B01AC06259T1001X B infarct, stroke, vascular 1 tablet daily occlusion and deep vein Glycine 45 mg Tablet X thrombosis. Transient ischaemic attacks 300 - 900 mg every 4 - 6 Acetylsalicylic Acid 300 mg N02BA01000T4001X hours as required. Max 4 g7 C Mild to moderate pain daily. Use in children not Soluble Tablet X recommendedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 1 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: initially 25-30 mg8 Acitretin 10 mg Capsule D05BB02000C1001 i) Severe form of psoriasis daily for 2-4 weeks, then XX including erythrodermic adjusted according to psoriasis and local or response, usually within generalized pustular range 25-50 mg daily for psoriasis. further 6-8 weeks (max: 75 ii) Severe disorders of mg daily). In disorders of A* keratinization, such as - keratinization, maintenance congenital ichthyosis - therapy of less than pityriasis rubra pilaris - 20mg/day and should not Darier's disease -other exceed 50mg/day CHILD: disorders of keratinization 0.5mg/kg daily occasionally which may be resistant to up to 1 mg/kg daily to a max. 35 mg daily for limited other therapies periods ADULT: initially 25-30 mg9 Acitretin 25 mg Capsule D05BB02000C1002 i) Severe form of psoriasis daily for 2-4 weeks, then XX including erythrodermic adjusted according to psoriasis and local or response, usually within generalized pustular range 25-50 mg daily for psoriasis. further 6-8 weeks (max: 75 ii) Severe disorders of mg daily). In disorders of A* keratinization, such as - keratinization, maintenance congenital ichthyosis - therapy of less than pityriasis rubra pilaris - 20mg/day and should not Darier's disease -other exceed 50mg/day CHILD: disorders of keratinization 0.5mg/kg daily occasionally which may be resistant to up to 1 mg/kg daily to a max. other therapies 35 mg daily for limited periods10 Acriflavine 0.1% Lotion D08AA03000L6001X C+ Infected skin, lesions, cuts, X abrasions, wounds and Apply undiluted three times burns. daily to the affected part.11 Actinomycin D L01DA01110P4001X A i) For solid tumours i) ADULT: 500 mcg IV daily (Dactinomycin) 500 mcg/ml X ii) Gestational trophoblastic for max of 5 days. CHILD: Injection disease 1.5 mg/m2 once every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500 mcg IV on Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg IV bolus on Days 1 and 2, repeat every 15 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 2 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE12 Acyclovir 200 mg Tablet J05AB01000T1001X CATEGORY i) Mucocutaneous Herpes i) ADULT: initially 400 mg 513 Acyclovir 200 mg/5 ml X A/KK Simplex infection in times daily for 7 - 14 days. Suspension immunocompromised and CHILD less than 2 years: 200 J05AB01000L8001X A* AIDS patients mg 4 times daily, CHILD X ii) Primary and recurrent more than 2 years: 400 mg 4 Varicella Zoster infection in times daily immunocompromised and ii), iii) and iv) ADULT: 200 - AIDS patients 400 mg 4 times daily. CHILD: iii) Severe Kaposi Varicella less than 2 years, half adult Eruption (Eczema dose; more than 2 years, herpeticum) adult dose iv) Severe primary HSV v) ADULT: 800 mg 5 times infections (eg. Neonatal daily for 7 days herpes, encephalitis, eczema vi) ADULT: 20 mg/kg herpeticum, genital herpes, (maximum: 800 mg) four gingival stomatitis, vaginal times daily for 5 days, CHILD delivery with maternal vulva 6 years: 800 mg four times herpes) daily. CHILD less than 2 v) Severe and complicated years; 400mg 4 times daily, varicella infection (eg. more than 2 years; 800mg 4 Encephalitis, purpura times daily fulminans) vi) Severe zoster infection in i) ADULT: initially 400 mg 5 paediatrics (eg. Encephalitis, times daily for 7 - 14 days. purpura fulminans, CHILD less than 2 years: 200 immunocompromised mg 4 times daily, CHILD patients and facial, sacral more than 2 years: 400 mg 4 and motor zoster) times daily. ii), iii) and iv) ADULT: 200 - i) Mucocutaneous Herpes 400 mg 4 times daily. CHILD: Simplex infection in less than 2 years, half adult immunocompromised and dose; more than 2 years, AIDS patients. adult dose. ii) Primary and recurrent v) ADULT: 800 mg 5 times Varicella Zoster infection in daily for 7 days immunocompromised and vi) ADULT: 20 mg/kg AIDS patients. (maximum: 800 mg) four iii) Severe Kaposi Varicella times daily for 5 days, CHILD Eruption (Eczema 6 years: 800 mg four times herpeticum). daily. CHILD less than 2 iv) Severe primary HSV years; 400mg 4 times daily, infections (eg. Neonatal more than 2 years; 800mg 4 herpes, encephalitis, eczema times daily. herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes). v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans). vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster).Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 3 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months14 Acyclovir 250 mg Injection J05AB01000P4001X A* Treatment and prophylaxis of with disseminated herpes X herpes simplex in simplex: 20mg/kg every 8 hourly for 14 days (21 days in immunocompromised, severe CNS involvement), varicella- initial genital herpes and zoster 10-20mg/kg every 8 hourly usually for 7 days. Varicella -Zoster CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8 hourly for varicella- zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis)15 Acyclovir 3% Eye Ointment S01AD03000G5101 A* Only for the treatment of Apply 1 cm 5 times daily. XX herpes simplex keratitis Continue for at least 3 days after healing Herpes simplex infections of D06BB03000G1001 the skin, including initial and Apply every 4 hours for 5 - 1016 Acyclovir 5% Cream XX A* recurrent labial and genital days herpes simplex infections i) Mucocutaneous Herpes Simplex infection in17 Acyclovir 800 mg Tablet J05AB01000T1002X A/KK immunocompromised and i) ADULT: initially 400 mg 5 X AIDS patients. times daily for 7 - 14 days. ii) Primary and recurrent CHILD less than 2 years: 200 Varicella Zoster infection in mg 4 times daily, CHILD immunocompromised and more than 2 years: 400 mg 4 AIDS patients. times daily. iii) Severe Kaposi Varicella ii), iii) and iv) ADULT: 200 - Eruption (Eczema 400 mg 4 times daily. CHILD: herpeticum). less than 2 years, half adult iv) Severe primary HSV dose; more than 2 years, infections (eg. Neonatal adult dose. herpes, encephalitis, eczema v) ADULT: 800 mg 5 times herpeticum, genital herpes, daily for 7 days gingival stomatitis, vaginal vi) ADULT: 20 mg/kg delivery with maternal vulva (maximum: 800 mg) four herpes). times daily for 5 days, CHILD v) Severe and complicated 6 years: 800 mg four times varicella infection (eg. daily. CHILD less than 2 Encephalitis, purpura years; 400mg 4 times daily, fulminans). more than 2 years; 800mg 4 vi) Severe zoster infection in times daily. paediatrics (eg. Encephalitis,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 4 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY18 Adalimumab 40 mg L04AB04000P5001X purpura fulminans, i) Severe rheumatoid arthritis, Injection X A* immunocompromised Psoriatic arthritis, Ankylosing patients and facial, sacral spondylitis: Subcutaneous 4019 Adapalene 0.1% Cream D10AD03000G1001 A* and motor zoster). mg every other week20 Adapalene 0.1% Gel XX A* ii) Chronic plaque psoriasis: i) Third line treatment of: - Initial, 80 mg SC, followed by D10AD03000G3001 Severe rheumatoid arthritis - 40 mg SC every other week XX Psoriatic arthritis - Ankylosing starting one week after the spondylitis after failure of initial dose conventional DMARDs or iii) & iv) Crohn's disease & other biologics Ulcerative colitis: 160mg at ii)Treatment of adults with week 0 (dose can be moderate to severe chronic administered as four plaque psoriasis who have injections in one day or as not responded to, have two injections per day for two contraindication or are consecutive days) and 80mg unable to tolerate at week 2. After induction phototherapy and/or systemic treatment, the recommended therapies including acitretin, maintenance dose is 40mg methotreaxate and every other week via cyclosporine subcutaneous injection. iii) Crohn's Disease Apply once daily to the a) For treatment of affected areas after washing moderately to severely active at bedtime Crohn's Disease in adult patients who have Apply once daily to the inadequate response to affected areas after washing conventional therapy at bedtime b) For treatment of moderately to severely active Crohn's Disease in adult patients who have lost response to or are intolerant to infliximab iv) Ulcerative Colitis - For treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment] Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoylUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 5 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY peroxide or topical tretinoin [third line treatment]21 Adefovir Dipivoxil 10 mg J05AF08000T1001X A* i) Treatment of chronic Adult (18-65 years): 10mg Tablet X HBeAg positive and HBeAg Once Daily Renal Dose negative hepatitis B infection Adjustment : 10mg every22 Adenosine 3 mg/ml C01EB10000P3001X B in adults with compensated 48hours (30-49ml/min); 10mg Injection X liver function (lamivudine every 72hours (10-29ml/min); should be tried first) 10mg every 7 days Adrenaline Acid C01CA24123P3001 B ii) Lamivudine-resistant (Hemodialysis)23 (Epinephrine) Tartrate 1 XX chronic hepatitis B virus infection with either ADULT: Initially: 3 mg given mg/ml Injection compensated or as a rapid IV bolus (over 2 decompensated hepatitis seconds). Second dose: If24 Aflibercept 40mg/ml S01LA05000P3001X A* function (only by hepatologist the first dose does not result solution vial for injection X and gastroenterologist for in elimination of the approved indications) supraventricular tachycardia25 Agomelatine 25 mg Tablet N06AX22000T1001X A* with in 1 or 2 minutes, 6 mg X Rapid conversion of should be given also as a paroxysmal supraventricular rapid IV bolus. Third dose: If26 Albendazole 200 mg Tablet P02CA03000T1001X C+ tachycardia to sinus rhythm the second dose does not X result in elimination of the Cardiopulmonary supraventicular tachycardia resuscitation with in 1-2 minutes, 12 mg should be given also as a Treatment of neovascular rapid IV bolus (wet) age-related macular 1 mg by intravenous injection degeneration (wet AMD). repeated every 3-5 minutes according to response Major depression The recommended dose is 2mg aflibercept, equivalent to i) Single or mixed infestations 0.05mL (50 μL) given as of intestinal parasites intra-vitreal injection. ii) Strongyloides infection Aflibercept treatment is initiated with one injection per month for three consecutive doses, followed by one injection every two months. The recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime. i) Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 6 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Child 12-24months: 200mg as a single dose27 Albendazole 200 mg/5 ml P02CA03000L8001X C+ i) Single or mixed infestations ii) Adult & Child above 2 Suspension X of intestinal parasites years: 400mg as a single ii) Strongyloides infection dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days28 Alcohol 70% Solution D08AX08000L9901X C+ Use as antiseptic and Apply to the skin undiluted or X disinfectant when needed 1 tablet once weekly Osteoporosis in [70mg/5600 IU]. Patient postmenopausal women with should receive supplemental a history of vertebral fracture calcium or vitamin D, if and whom oestrogen dietary vitamin D inadequate. replacement therapy is The tablet should be taken at contraindicated. Review least half and hour before the treatment after 2 years and if first food, beverage, or Alendronate Sodium 70 mg there is positive response, medication of the day with and Cholecalciferol 5600 IU29 Tablet M05BB03972T1002 A* treatment may be continued plain water only. To facilitate XX up to 5 years and then re- delivery to stomach and thus evaluate. Treatment should reduce the potential for be stopped if there is no esophageal irritation, it positive response after 5 should only be swallowed years. Otherwise, patient upon arising for the day with needs to be given drug a full glass of water and holiday for 1 to 2 years and patient should not lie down then continue treatment shall for at least 30 minutes and the benefit outweigh the risk. until after their first food of the day. Osteoporosis in postmenopausal women with a history of vertebral fracture and whom oestrogen 70 mg once weekly. Swallow replacement therapy is contraindicated. Review the tablet whole with a full treatment after 2 years and if glass of plain water only on there is positive response, an empty stomach at least 3030 Alendronate Sodium 70 mg M05BA04520T1001 A* treatment may be continued minutes before breakfast Tablet XX up to 5 years and then re- (and any other oral evaluate. Treatment should medication); stand or sit be stopped if there is no upright for at least 30 positive response after 5 minutes and do not lie down years. Otherwise, patient until after eating breakfast needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. i) Renal osteodystrophy in patients on haemodialysis Initial dose ADULT and ii) Hypoparathyroidism and CHILD above 20kg body Alfacalcidol 0.25 mcg A11CC03000C1001 pseudohypoparathyroidism weight: 1 mcg daily; CHILD31 Capsule XX A/KK iii) Adjunct to the under 20kg body weight: 0.05 management of tertiary mcg/kg/day. Maintenance hyperparathyroidism dose : 0.25 mcg to 2 mcg iv) Rickets and osteomalacia daily v) OsteoporosisUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 7 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Renal osteodystrophy in patients on haemodialysis Initial dose ADULT and ii) Hypoparathyroidism and CHILD above 20kg body pseudohypoparathyroidism weight: 1 mcg daily; CHILD A11CC03000C100232 Alfacalcidol 1 mcg Capsule XX A/KK iii) Adjunct to the under 20kg body weight: 0.05 management of tertiary mcg/kg/day. Maintenance hyperparathyroidism dose : 0.25 mcg to 2 mcg iv) Rickets and osteomalacia daily v) Osteoporosis i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism A11CC03000D500133 Alfacalcidol 2 mcg/ml Drops XX A* iii) Adjunct to the NEONATES : 0.1 mcg/kg/day management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis Treatment of:34 Alfacalcidol 2 mcg/ml A11CC03000P3001 A* i) Renal osteodystrophy in Adult: Initially, 1 mcg daily. Injection XX patients on haemodialysis Maintenance: 0.25-1 mcg ii) Hypoparathyroidism and daily. Child: Premature pseudohypoparathyroidism infants and neonates: 0.05- iii) Adjunct to the 0.1 mcg/kg daily; <20 kg: management of tertiary 0.05 mcg/kg daily. Elderly: hyperparathyroidism 0.5 mcg daily. iv) Rickets and osteomalacia v) Osteoporosis For use as short acting Initial dose: 20 - 40 mcg/kg.35 Alfentanil HCl 0.5 mg/ml N01AH02110P3001 A* narcotic analgesic in short Supplemental dose: 15 Injection XX procedures and day-care mcg/kg or infusion 0.5 - 1.0 surgical procedures mcg/kg/min Treatment of functional36 Alfuzosin HCl 10 mg Tablet G04CA01110T1001 A* symptoms related with 10 mg once a day pre bed XX benign prostatic hypertrophy (BPH) 20 mg/kg of body weight administered once every 2 weeks as an intravenous infusion. Monitoring It is suggested that patients be monitored periodically for IgG antibody formation. Patients who experience Infusion- Alglucosidase alfa 5 mg/ml A16AB07000P4001X Infantile-onset Pompe associated reactions Injection X disease suggestive of hypersensitivity37 A* may be tested for IgE antibodies to alglucosidase alfa. Treated patients who experience a decrease in benefit despite continued treatment with Alglucosidase Alfa, in whom antibodies are suspected to play a role, may be tested for neutralization of enzyme uptake or activity.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 8 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY38 Alkaline Nasal Douche R01A000999L5001X B To remove nasal plug To be diluted with an equal X volume of warm water before use i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. Initial dose: 100-300 mg M04AA01000T1002 iii) The presence of daily. Maintenance: 300-60039 Allopurinol 100 mg Tablet XX A/KK tophaceous deposits. mg daily. Maximum: 900 mg iv) Urate nephropathy. daily v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. Initial dose: 100-300 mg M04AA01000T1001 iii) The presence of daily. Maintenance: 300-60040 Allopurinol 300 mg Tablet XX A/KK tophaceous deposits. mg daily. Maximum: 900 mg iv) Urate nephropathy. daily v) Urate nephrolithiasis. vi) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance:41 All-Trans Retinoic Acid 10 L01XX14000C1001X A* Acute promyelocytic 45 mg/m2 daily for 2 weeks mg Capsule X leukaemia every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.2542 Alprazolam 0.25 mg Tablet N05BA12000T1001X A/KK Anxiety disorders mg 2-3 times daily), X increased if necessary to a total dose of 3 mg/day. Not recommended for children 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.2543 Alprazolam 0.5 mg Tablet N05BA12000T1002X A Anxiety disorders mg 2-3 times daily), X increased if necessary to a total dose of 3 mg/day. Not recommended for children 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.2544 Alprazolam 1 mg Tablet N05BA12000T1003X A Anxiety disorders mg 2-3 times daily), X increased if necessary to a total dose of 3 mg/day. Not recommended for childrenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 9 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 0.05 - 0.1 mcg/kg/min by45 Alprostadil 500 mcg/ml C01EA01000P3001X A* For treatment of congenital continuous IV infusion, then Injection X heart diseases which are decreased to lowest effective ductus arteriosus dependent dose 0.9 mg/kg (maximum of 9046 Alteplase 50 mg per vial B01AD02000P4001X A* Thrombolytic treatment of mg) infused over 60 minutes Injection X acute ischaemic stroke. with 10% of the total dose administered as an initial47 Aluminium Hydroxide 600 A02AB01250T1001X A Dyspepsia, intravenous bolus. Treatment mg Tablet X hyperphosphataemia must be started as early as possible within 4.5 hours48 Amantadine HCl 100 mg N04BB01110C1001 B Parkinson's disease after onset of stroke Capsule XX symptoms and after exclusion of intracranial49 Amikacin 125 mg/ml J01GB06183P3003X A Infections due to susceptible haemorrhage by appropriate Injection X organisms imaging technique. 600 mg- 1.2 g 4 times daily50 Amikacin 250mg/ml J01GB06183P3002X A Infections due to susceptible and at bedtime or as required Injection X organisms Initial dose: 100 mg daily and is increased to 100 mg twice Amiloride HCl 5 mg & i) Diuretic as an adjunct to daily (not later than 4 p.m.)51 Hydrochlorothiazide 50 mg after a week. Elderly over 65 C03EA01900T1001X B the management of years: less than 100 mg or Tablet X oedematous states 100 mg at intervals of more ii) Hypertension than 1 day52 Amino Acids Injection ADULT: (IM or IV): 15 B05BA01910P3001X A Source of amino acids in mg/kg/day 8 - 12 hourly for 7 X patients needing IV nutrition - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day i) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose Dose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 10 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY53 Amino Acids with B05BA10910P3002X A Source of amino acids and Dose to be individualised. Electrolytes Injection X electrolytes in patients ADULT usual requirement for needing IV nutrition amino acid 1-2 g/kg/day Amino Acids with Glucose B05BA10910P3003X Source of amino acids, Dose to be individualised. with Electrolytes Injection X carbohydrate and electrolytes ADULT usual requirement for54 A in patients needing IV amino acid 1-2 g/kg/day, nutrition carbohydrate 4-6 g/kg/day Dose to be individualised.55 Amino Acids, Glucose and B05BA10910P3001X A Source of amino acids, ADULT: 500 - 2000 ml daily Lipid with Electrolytes X carbohydrate, lipid and given by IV. ADULT usual Injection electrolytes in patients requirement for amino acid 1- needing IV nutrition 2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day Adult: Loading dose: 5 mg/kg (ideal body weight) or 250- 500 mg (25 mg/ml) by slow inj or infusion over 20-30 min.56 Aminophylline 25 mg/ml R03DA05000P3001 B Reversible airways Maintenance infusion dose: Injection XX obstruction, acute severe 0.5 mg/kg/hr. Max rate: 25 brochospasm mg/min. Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr. 200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another57 Amiodarone 200 mg Tablet C01BD01110T1001X A* Arrhythmias week. Maintenance dose, X usually 200 mg daily or the minimum required to control the arrhythmia Initial infusion of 5mg/kg via large venous access over 20-58 Amiodarone 50 mg/ml C01BD01110P3001 A* Arrhythmias when other 120 minutes with ECG Injection XX drugs are contraindicated or monitoring; subsequent ineffective infusion given if necessary according to response up to a maximum of 1.2 g in 24 hours Treatment of psychoses, Predominantly negative particularly acute or chronic episodes: 50-300 mg once schizophrenia disorders daily adjusted according to characterized by positive the patient?s response. symptoms(e.g. delusion, Mixed episodes with positive59 Amisulpride 100 mg Tablet N05AL05000T1001X A* hallucinations, thought and negative symptoms: 400- X disorders) and/or negative 800 mg/day in 2 divided symptoms(e.g. blunted doses adjusted according to emotions, emotional and the patient?s response. social withdrawal) including Should be taken on an empty when the negative symptoms stomach (Preferably taken predominate before meals) Treatment of psychoses, Predominantly negative particularly acute or chronic episodes: 50-300 mg once60 Amisulpride 400 mg Tablet N05AL05000T1002X A* schizophrenia disorders daily adjusted according to X characterized by positive the patient?s response. symptoms(e.g. delusion, Mixed episodes with positive hallucinations, thought and negative symptoms: 400-Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 11 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY disorders) and/or negative 800 mg/day in 2 divided symptoms(e.g. blunted doses adjusted according to emotions, emotional and the patient?s response. social withdrawal) including Should be taken on an empty when the negative symptoms stomach (Preferably taken predominate before meals) Initially 25mg 3 times a day. Maintenance: 25-100mg daily in divided doses. Hospitalized patient: 100mg/day &gradually61 Amitriptyline HCl 25 mg N06AA09110T1001X B Depression increase to 200-300mg/day. Tablet X ADOLESCENT and ELDERLY: initially 20- 30mg/day in divided doses w/ gradual increments. CHILD under 16 years are not recommended Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 1062 Amlodipine 10 mg and C09DB01935T1003X A/KK Essential hypertension in mg/valsartan 320 mg Valsartan 160 mg Tablet X patients whose blood ORALLY once daily, with pressure is not adequately dose titration occurring every controlled by monotherapy 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg63 Amlodipine 10 mg Tablet C08CA01000T1002X B Hypertension 5 mg once daily. Max: 10 mg X once daily Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 1064 Amlodipine 5 mg and C09DB01935T1002X A/KK Essential hypertension in mg/valsartan 320 mg Valsartan 160 mg Tablet X patients whose blood ORALLY once daily, with pressure is not adequately dose titration occurring every controlled by monotherapy 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg65 Amlodipine 5 mg Tablet C08CA01000T1001X B Hypertension 5 mg once daily. Max: 10 mg X once daily One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients Amlodipine besylate 10mg, Treatment of essential receiving valsartan, hypertension. This fixed amlodipine and HCTZ from66 valsartan 160mg, C09DX01941T1001X A/KK combination drug is not seperate tablets may be hydrochlorothiazide 12.5mg X indicated for the initial switched to amlodipine therapy of hypertension. besylate/valsartan/HCTZ tablet containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipineUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 12 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY besylate/valsartan/HCTZ is Amlodipine besylate 10mg, Treatment of essential reached within 2 weeks of hypertension. This fixed change in dose. The67 valsartan 160mg, C09DX01941T1002X A/KK combination drug is not maximum recommended hydrochlorothiazide 25mg X indicated for the initial dose of amlodipine tablet therapy of hypertension. besylate/valsartan/HCTZ is 10/320/25 mg. It can be Amlodipine besylate Treatment of essential taken with or without food. It 5mg,valsartan C09DX01941T1004X hypertension. This fixed is recommended to take it68 A/KK combination drug is not with some water. 160mg,hydrochlorothiazide X indicated for the initial One tablet daily 12.5mg tablet therapy of hypertension. i) A patient whose blood pressure is not adequatelyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water. One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is 13 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY reached within 2 weeks of Treatment of essential change in dose. The maximum recommended69 Amlodipine Camsylate 5 mg C09DB06935T1002X A/KK hypertension in adults dose of amlodipine and Losartan Potassium X patients whose blood besylate/valsartan/HCTZ is 100 mg Tablet pressure is not adequately 10/320/25 mg. It can be controlled on either taken with or without food. It is recommended to take it monotherapy with some water. Treatment of essential Amlodipine 5mg/losartan 50mg OR amlodipine70 Amlodipine Camsylate 5 mg C09DB06935T1001X A/KK hypertension in adults 5mg/losartan 100mg orally and Losartan Potassium 50 X patients whose blood once daily. MAXIMUM mg Tablet pressure is not adequately DOSE: amlodipine controlled on either 5mg/losartan 100mg. No monotherapy dosage adjustment in mild renal impairment. Not71 Ammonium Bicarbonate, R05CA04900L2101X C Cough recommended in moderate to severe renal impairment or in Tincture Ipecac, etc Mixture X patients on dialysis. Not recommended in patients72 Amorolfine 5 % Nail D01AE16110L5001X A* Fungal nail infections who require lower dose of Lacquer X losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group Amlodipine 5mg/losartan 50mg OR amlodipine 5mg/losartan 100mg orally once daily. MAXIMUM DOSE: amlodipine 5mg/losartan 100mg. No dosage adjustment in mild renal impairment. Not recommended in moderate to severe renal impairment or in patients on dialysis. Not recommended in patients who require lower dose of losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group Adults, the elderly and children over 12 years: 10- 20ml, repeated after 4 hours if required. Not more than 4 doses to be taken in any 24 hours. Apply to affected nail once or sometimes twice a week after filling and cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 14 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY months (review at intervals of 3 months) Mild to Moderate infection: 25mg/kg/day (based on73 Amoxicillin & Clavulanate J01CR02961F2102X A/KK Infections caused by Amoxicillin dose) in 2 divided 228 mg/5 ml Syrup X susceptible organisms dose. Severe infection: 45mg/kg/day (based on Amoxicillin dose) in 2 divided dose Amoxicillin 1 g & J01CR02961P4002X A Infections caused by CHILD less than 3 months:74 Clavulanate 200 mg X 30mg/kg 12 hourly. 3 months susceptible organisms. - 12 years: 30mg/kg 6 - 8 Injection Respiratory tract, skin, soft hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 tissue, GUT infection, hourly septicaemia, peritonitis, post- operative infection & osteomyelitis Infections caused by ADULT: 250 - 500 mg 375 Amoxicillin 250 mg Capsule J01CA04012C1001X B susceptible strains of gram times daily. CHILD: 20 - 40 X positive and gram negative mg/kg/day in divided doses 8 organisms hourly Infections due to beta- lactamase producing strain where amoxicillin alone is not ADULT & CHILD more than76 Amoxicillin 500 mg & J01CR02961T1002X A/KK appropriate. Respiratory 12 years: Mild to moderate Clavulanate 125 mg Tablet X tract, skin, soft tissue, GUT infections: 625 mg twice infection, septicaemia, daily. peritonitis, post-operative infection & osteomyelitis Amoxicillin 500 mg and J01CR02961P4001X A Infections caused by CHILD less than 3 months:77 Clavulanate 100 mg X susceptible organisms. 30mg/kg 12 hourly. 3 months Respiratory tract, skin, soft - 12 years: 30 mg/kg 6 - 8 Injection tissue, GUT infection, hourly. ADULT: 1.2 g by IV or septicaemia, peritonitis, post- intermittent infusion 6 - 8 operative infection and hourly osteomyelitis Infections caused by ADULT: 250 - 500 mg 3 J01CA04012C1002X susceptible strains of gram times daily. CHILD: 20 - 4078 Amoxicillin 500 mg Capsule X B positive and gram negative mg/kg/day in divided doses 8 organisms hourly79 Amoxicillin Trihydrate 125 J01CA04012F1001X B Infections caused by CHILD less than 10 years: mg/5 ml Syrup X susceptible strains of gram 125 - 250 mg 8 hourly. positive and gram negative CHILD less than 20 kg: 20 - organisms 40 mg/kg/day in 3 - 4 divided doses80 Amphotericin B 0.15% Eye S01A000801D2002X A Fungal infection of the 1 drop hourly or 2 hourly Drops X cornea81 Amphotericin B 0.25% Eye S01A000801D2003X A Fungal infection of the 1 drop hourly or 2 hourly Drops X cornea ADULT: 0.25 mg/kg/day by IV infusion, gradually82 Amphotericin B 50 mg J02AA01801P4001X A Systemic fungal infections increase if tolerated to 1 Injection X mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 15 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY For neonates, lower doses Ampicillin Sodium & J01CR01961F2101X A Treatment of susceptible are recommended83 Sulbactam Sodium 250 X bacterial infections ADULT: (1-) 2-6g daily mg/5 ml Suspension CHILDREN: (25-) 50- 100mg/kg daily84 Ampicillin Sodium & J01CR01961T1001X A/KK Treatment of susceptible PREMATURE AND Sulbactam Sodium 375 mg X bacterial infections NEWBORNS: 25-50mg/kg Tablet daily ADULT: 375-750mg twice85 Ampicillin Sodium 1g & J01CR01961P4002X A Treatment of susceptible daily CHILDREN AND Sulbactam Sodium 500mg X bacterial infections INFANTS: 25-50mg/kg/day in Injection 2 divided doses, if ≥ 30kg use an adult dose ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly.86 Ampicillin Sodium 500 mg & J01CR01961P4001X A Treatment of susceptible Maximum: 4 g Sulbactam per Sulbactam Sodium 250 mg X bacterial infections day. CHILD: 150- Injection 300mg/kg/day 6 - 8 hourly. Prophylaxis: 1.5 -3 g at induction of anaesthesia. May be repeated 6 - 8 hourly 250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 Ampicillin Sodium 500 mg J01CA01520P4001X Treatment of susceptible mg/kg/day. Meningitis: 2 g 6 Injection X bacterial infections (non beta- hourly. CHILD: 15087 B lactamase-producing mg/kg/daily IV in divided organisms); meningitis doses. Usual children dose less than 10 years, half adult dose88 Ampicillin Trihydrate 125 J01CA01012F2101X B Treatment of susceptible CHILD: 50 - 100 mg/kg/day 4 mg/5 ml Suspension X bacterial infections (non beta- times daily. Under 1 year: lactamase-producing organisms) 62.5 - 125 mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily Treatment of hormone89 Anastrozole 1 mg Tablet L02BG03000T1001X A* responsive metastatic or 1 mg daily X locally advanced breast cancer after failure of tamoxifen90 Anidulafungin 100mg J02AX06000P3001X A* Treatment of invasive Loading dose of 200 mg on Injection X candidiasis, including day 1, then 100 mg once candidemia in adults when daily thereafter for at least 14 intolerance or resistance to days after the last positive Amphotericin B or culture. FluconazoleUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 16 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Antazoline HCl, Hay fever, conjunctivitis, ADULT: Instill 1 drop, 3 - 4 allergic conjunctivitis, vernal times daily, into the lower91 Tetrahydrozoline HCl and S01GA52110D2001 A/KK keratoconjunctivitis and eyelid. CHILD 2 - 12 years : Benzalkonium Cloride Eye XX eczematosa Instill 1 drop daily or twice Drops daily Prevention of Rh(D) i) Antepartum prophylaxis: sensitisation to Rh(D)- negative woman: The recommended dose is a i) Pregnancy/delivery of single dose of 300mcg Rh(D)-positive infant administered by IV or IM ii) Abortion/threatened injection ii) Postpartum92 Anti RhD Gamma Globulin J06BB01000P3001X B abortion, ectopic pregnancy prophylaxis: 300mcg should 300 mcg/2 ml Injection (150 X or hydatidiform mole be administered as soon as mcg = 750 IU) iii) Transplacental possible after delivery and no haemorrhage resulting from later than 72 hours antepartum haemorrhage, thereafter, by IV or IM route. amniocentesis, chorionic If the 72-hour limit is biopsy or obstetric exceeded, anti-Rh (D) manipulative procedures e.g. immunoglobulin must be external version or abdominal administered anyway. trauma i) To be used when conventional anti-rejection therapy is not successful ii) Treatment of aplastic anaemia not responding to oxymethalone after 3 months, in which there is persistent pancytopenia with repeated attacks of 10 - 30 mg/kg body weight septicaemia and bleeding. daily. Slow IV infusion (over93 Antilymphocyte/Antithymocy L04AA03000P3001X A* iii) Severe aplastic anaemia at least 4 hours) diluted in te Immunoglobulin (from X with the following 250 - 500 ml Normal Saline. Horse) Injection parameters: For Graft versus host disease a) Granulocyte less than treatment:40 mg/kg/day 0.5x109/L b) Platelet less than 20x109/L c) Reticulocyte less than 20x109/L iv) As a conditioning regime prior to transplant. v) Graft-versus-host disease treatment94 Antirabies Immunoglobulin J06BB05000P3001X B Treatment of rabies, post- 20 iu/kg; half by IM and half (Human) 300 iu/2ml X exposure by infiltration around the wound Antithymocyte L04AA04000P3001X A* i) Prophylaxis of acute graft i) 1.0 - 1.5 mg/kg/day for 2 - 995 Immunoglobulin (from X rejection days after transplantation of ii) Treatment of acute graft a kidney, pancreas or liver, rabbit) Injection rejection for 2 - 5 days after heart iii) Prophylaxis of acute and transplantation chronic graft versus host ii) 1.5 mg/kg/day for 3 - 14 disease days iii) 2.5 - 5.0 mg/kg/day iv) Treatment of steroid- for 4 days resistant, acute graft versus iv )2.5 - 5.0 mg/kg/day for 5 host disease v)Treatment of days aplastic anemiaUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 17 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY v )2.5 - 3.5 mg/kg/day for 5 days96 Antivenene Cobra Injection J06AA03000P3002X B Treatment of patients who Initial dose of 100ml of X exhibit manifestations of reconstituted antivenene systemic envenoming given by slow intravenous97 Antivenene Pit Viper J06AA03000P3001X B following a bite by Cobra infusion (2ml/min). Injection X (Naja kaouthia). Subsequent dose can be given every 12 hours Treatment of patients who according to the clinical exhibit manifestations of symptoms. As product may systemic envenoming differ from batches and following a bite by Malayan manufacturer, it is strongly Pit Viper (Calloselasma recommended to refer to the rhodostoma). product insert on dosing recommendation. Initial dose of 30ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 6 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.98 Antivenene Serum (Sea J06AA03000P3003X B Treatment of patients who 1000 units by IV infusion over snake) 1000 units Injection X exhibit manifestations of 1/2 to 1 hour. In severe systemic envenoming cases 3000 -10000 units may99 Antivenene Serum Snake J06AA03000P3004X B following a bite by sea snake. be required Polyvalent Injection X Recommended initial dose is Treatment of patients who 20ml by intravenous infusion.100 Aprepitant 125 mg Capsule A04AD12000C1002 A* exhibit manifestations of The injection should be given XX systemic envenoming very slowly as 5 minutes by following a bite by Indian direct slow intravenous route101 Aprepitant 80 mg Capsule A04AD12000C1001 A* Cobra (Naja naja), Common or 1hour by infusion. If XX Krait (Bungarus caeruleus), symptoms continue, further Russell's Viper (Daboia doses are administered as russelli) and Saw-scaled required until symptoms Viper (Echis carinatus). completely disappear. In combination with other 125 mg 1 hour prior to antiemetic agents for chemotherapy on Day 1. To prevention of delayed nausea be given as part of a 3-day and vomiting associated with regimen that includes a initial and repeat course of corticosteroid and a 5-HT3 highly emetogenic antagonist chemotherapy In combination with other 80 mg once daily in the antiemetic agents for morning on Days 2 and Day prevention of delayed nausea 3. To be given as part of a 3- and vomitting associated with day regimen that includes a initial and repeat course ofUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 18 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY highly emetogenic corticosteroid & a 5-HT3 chemotherapy antagonist All patients should receive a 1 ml IV test dose at least 10 minutes prior to loading dose. Initially 2 million KIU bolus102 Aprotinin 10,000 KIU/ml B02AB01000P3001X A* Only for Open Heart Surgery followed by 2 million KIU in Injection X (extracorporeal circulation) heart-lung machine followed by a slow infusion of 500,000 KIU/hr until end of surgery. CHILD: 20,000 KIU/kg/day103 Aqueous Cream D02AX00000G1001 C+ Dry skin As a soap or apply to the skin XX as an emollient cream104 Aripiprazole 10mg Tablet N05AX12000T1001X A* i) Treatment of acute Schizophrenia: 10 or 15 X episodes of schizophrenia mg/day. Maintenance dose: and for maintenance of 15 mg/day. Bipolar mania: clinical improvement during Starting dose: 15 or 30 continuation therapy. mg/day. Dose adjustment ii) Treatment of acute manic should occur at intervals of episodes associated with not less than 24 hour bipolar I disorder i) Treatment of acute episodes of schizophrenia Schizophrenia: 10 or 15 and for maintenance of mg/day. Maintenance dose:105 Aripiprazole 15mg Tablet N05AX12000T1002X A* clinical improvement during 15 mg/day. Bipolar mania: X continuation therapy. Starting dose: 15 or 30 ii) Treatment of acute manic mg/day. Dose adjustment episodes associated with should occur at intervals of bipolar I disorder not less than 24 hour Induction: 0.15 mg/kg/day IV until bone marrow remission. Total induction dose ≤ 60 Relapsed acute doses. Consolidation : 0.15106 Arsenic Trioxide 1 mg/ml L01XX27550P3001X A* promyelocytic leukaemia mg/kg/day IV for 25 doses in Injection X (APML). To be prescribed by 5 weeks (5 days per week, consultant haematologist followed by 2 days only interruption; treatment should begin 3-6 weeks after completion of induction therapy). ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours107 Artemether 20mg + P01BE52981T1001X B Acute uncomplicated and then 4 tablets twice daily Lumefantrine 120mg X falciparum malaria (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tabletsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 19 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY per dose, depending on bodyweight Weight 5-8kg, Age 6-11 months, Dose: One tablet Artesunate 100 mg and P01BF02000T1002X A Treatment of acute 25/55mg OD x 3 days Weight108 Mefloquine HCI 220 mg X uncomplicated Plasmodium : 9-17kg, Age 1-6 years, falciparummalaria, resulting Dose : Two tablet 25/55mg Tablet either from P. falciparum OD x 3 days Weight :18- mono-infection or mixed 29kg, Age 7-12 years, Dose infection with P. vivax. :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days Weight 5-8kg, Age 6-11 months, Dose: One tablet Artesunate 25 mg and P01BF02000T1001X A Treatment of acute 25/55mg OD x 3 days Weight109 Mefloquine HCI 55 mg X uncomplicated Plasmodium : 9-17kg, Age 1-6 years, falciparummalaria, resulting Dose : Two tablet 25/55mg Tablet either from P. falciparum OD x 3 days Weight :18- mono-infection or mixed 29kg, Age 7-12 years, Dose infection with P. vivax. :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days 2.4mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment110 Artesunate 60 mg Injection P01BE03000P3001X A Treatment of severe malaria can be substituted. For adults X caused by Plasmodium and children with severe falciparum in adults and malaria or who are unable to children tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment. ADULT: 100-250 mg once or111 Ascorbic Acid 100 mg A11GA01000T1002X C+ Vitamin C deficiency twice daily CHILD: 100 mg Tablet X three times daily for one week followed by 100mg daily until symptoms abate. ADULT: 100-250 mg once or112 Ascorbic Acid 500 mg A11GA01000T1003X C+ Vitamin C deficiency twice daily CHILD: 100 mg Tablet X three times daily for one week followed by 100mg daily until symptoms abate.113 Ascorbic Acid 500 mg/2 ml A11GA01000P3001 B For prevention and treatment Therapeutic: Not less than Injection XX of scurvy 250 mg daily in divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 20 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY For second or third line i) Schizophrenia: - Acute treatment in adult for: treatment in adults: i) Schizophrenia Recommended starting and ii) Bipolar Disorder - target dose of asenapine is Monotherapy: Acute 5mg given twice daily. - Asenapine 10mg Sublingual N05AH05253T7002X treatment of manic or mixed Maintenance dose: 5mg episodes associated with twice daily.114 Tablet X A* Bipolar I disorder. - ii) Bipolar Disorder: - Adjunctive therapy: As Monotherapy: 10mg twice adjunctive therapy with either daily. Adjunctive therapy: lithium or valproate for the 5mg twice daily with lithium acute treatment of manic or or valproate. Dose can be mixed episodes associated increased to 10mg twice daily with Bipolar I Disorder. based on clinical response. For second or third line i) Schizophrenia: - Acute treatment in adult for: treatment in adults: i) Schizophrenia Recommended starting and ii) Bipolar Disorder - target dose of asenapine is Monotherapy: Acute 5mg given twice daily. - treatment of manic or mixed Maintenance dose: 5mg115 Asenapine 5mg Sublingual N05AH05253T7001X A* episodes associated with twice daily. Tablet X Bipolar I disorder. - ii) Bipolar Disorder: - Adjunctive therapy: As Monotherapy: 10mg twice adjunctive therapy with either daily. Adjunctive therapy: lithium or valproate for the 5mg twice daily with lithium acute treatment of manic or or valproate. Dose can be mixed episodes associated increased to 10mg twice daily with Bipolar I Disorder. based on clinical response.116 Atenolol 100 mg Tablet C07AB03000T1002X B Hypertension, angina Hypertension and arrythmias; X pectoris, myocardial 50 - 100 mg daily, Angina; infarction and arrhythmias 100 mg daily, Myocardial infarction; individualised117 Atenolol 50 mg Tablet C07AB03000T1001X B Hypertension, angina Hypertension and arrythmias; X pectoris, myocardial 50 - 100 mg daily, Angina; infarction and arrhythmias 100 mg daily, Myocardial infarction; individualised CHILD and ADOLESCENTS up to 70 kg: Initially 0.5118 Atomoxetine HCl 10 mg N06BA09110C1001 A* Attention deficit hyperactivity mg/kg/day for at least 7 days, Capsule XX disorder (ADHD) in children 6 then increased according to years and older who do not response. Maintenance: 1.2 respond to methylphenidate mg/kg/day. ADULTS and or who have intolerable ADOLESCENTS more than effects or have tics. 70 kg: Initially 40 mg/day for Diagnosis should be made at least 7 days then according to DSM IV criteria increased according to or the guidelines in ICD-10 response. Maintenance: 80 mg/day. Max 100 mg/ day Attention deficit hyperactivity CHILD and ADOLESCENTS disorder (ADHD) in children 6 up to 70 kg: Initially 0.5 years and older who do not mg/kg/day for at least 7 days, Atomoxetine HCl 18 mg N06BA09110C1002 respond to methylphenidate then increased according to Capsule XX119 A* or who have intolerable response. Maintenance: 1.2 effects or have tics. mg/kg/day. ADULTS and Diagnosis should be made ADOLESCENTS more than according to DSM IV criteria 70 kg: Initially 40 mg/day for or the guidelines in ICD-10 at least 7 days thenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 21 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY120 Atomoxetine HCl 25 mg N06BA09110C1003 Attention deficit hyperactivity increased according to Capsule XX A* disorder (ADHD) in children 6 response. Maintenance: 80 years and older who do not mg/day. Max 100 mg/ day121 Atomoxetine HCl 40 mg N06BA09110C1004 A* respond to methylphenidate CHILD and ADOLESCENTS Capsule XX or who have intolerable up to 70 kg: Initially 0.5 A* effects or have tics. mg/kg/day for at least 7 days,122 Atomoxetine HCl 60mg N06BA09110C1005 A/KK Diagnosis should be made then increased according to Capsule XX A/KK according to DSM IV criteria response. Maintenance: 1.2 A/KK or the guidelines in ICD-10 mg/kg/day. ADULTS and123 Atorvastatin 20 mg Tablet C10AA05000T1002X ADOLESCENTS more than124 Atorvastatin 40 mg Tablet X Attention deficit hyperactivity 70 kg: Initially 40 mg/day for125 Atorvastatin 80 mg Tablet disorder (ADHD) in children 6 at least 7 days then C10AA05000T1001X years and older who do not increased according to X respond to methylphenidate response. Maintenance: 80 or who have intolerable mg/day. Max 100 mg/ day C10AA05000T1004X effects or have tics. CHILD and ADOLESCENTS X Diagnosis should be made up to 70 kg: Initially 0.5 according to DSM IV criteria mg/kg/day for at least 7 days, or the guidelines in ICD-10 then increased according to response. Maintenance: 1.2 Attention deficit hyperactivity mg/kg/day. ADULTS and disorder (ADHD) in children 6 ADOLESCENTS more than years and older who do not 70 kg: Initially 40 mg/day for respond to methylphenidate at least 7 days then or who have intolerable increased according to effects or have tics. response. Maintenance: 80 Diagnosis should be made mg/day. Max 100 mg/ day according to DSM IV criteria CHILD and ADOLESCENTS or the guidelines in ICD-10 up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days, Hypercholesterolaemia and then increased according to coronary heart disease response. Maintenance: 1.2 intolerant or not responsive mg/kg/day. ADULTS and to other forms of therapy ADOLESCENTS more than Hypercholesterolaemia and 70 kg: Initially 40 mg/day for coronary heart disease at least 7 days then intolerant or not responsive increased according to to other forms of therapy response. Maintenance: 80 Hypercholesterolaemia and mg/day. Max 100 mg/ day coronary heart disease intolerant or not responsive 10 mg once daily. Maximum: to other forms of therapy 80 mg daily 10 mg once daily. Maximum: 80 mg daily 10 mg once daily. Maximum: 80 mg dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 22 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Initial intravenous bolus dose of 6.75mg (using 7.5mg/ml To delay imminent preterm solution for injection). birth in pregnant women with Immediately followed by a i) Regular uterine continuous high dose contractions of at least 30 infusion (loading infusion 300 seconds duration at a rate of mcg/min using 7.5mg/ml126 Atosiban 7.5 mg/ml G02CX01122P3001 ≥ 4 per 30 minutes concentrate for solution for Injection XX A* ii) A cervical dilation of 1 to 3 infusion) during three hours, cm (0 - 3 nulliparas) and followed by lower infusion of effacement of ≥ 50% 100mcg/min up to 45 hours. iii) Age ≥ 18 years Duration of treatment should iv) A gestational age from 28 not exceed 48 hours. Total until 33 completed weeks dose given during a full v) A normal foetal heart rate. course should not exceed 330mg of the active substance. Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6127 Atracurium Besylate 10 mg M03AC04197P3001 A* Muscle relaxant in general mg/kg. Supplementary dose: /ml in 2.5 ml Injection XX anaesthesia, Endotracheal 0.1-0.2 mg/kg as required. intubation, Aid controlled Continuous infusion rates of ventilation. 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure. Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal128 Atracurium Besylate 10 mg M03AC04197P3002 A* Muscle relaxant in general intubation dose: 0.5-0.6 /ml in 5 ml Injection XX anaesthesia, Endotracheal mg/kg. Supplementary dose: intubation, Aid controlled 0.1-0.2 mg/kg as required. ventilation. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure. Atropine Sulphate 0.3%, Subconjunctival injection to dilate pupils resistant to129 Cocaine HCl 1.7%, S01F000183P3001X A topical mydriatics 1 - 2 drops Adrenaline Acid Tartrate X 0.03% Mydriatic Injection PREOPERATIVE MYDRIASIS: one drop of a 1% solution supplemented Determination of refraction, with one drop of 2.5 or 10% strabismus, iritis and phenylephrine prior to130 Atropine Sulphate 1% Eye S01FA01183D2001X B iridocyclitis, after extra or surgery. Drops X intracapsular extraction of ANTERIOR UVEITIS or lens POSTOPERATIVE MYDRIASIS : one drop of a 1% or 2% solution up to 3 times a dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 23 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY131 Atropine Sulphate 1mg/ml A03BA01183P3001X i) Reduce vagal i) Adult: 300-600 mcg IM/SC Injection X B inhibition,salivary and 30-60 minutes before bronchiol secretion in anaesthesia. Alternatively, Azacitidine Powder for L01BC07000P4001X A* anaesthesia 300-600 mcg IV immediately132 suspension for injection X A ii) Reversal of excessive before induction of bradycardia anaesthesia. Child: >20 kg: 100mg/vial L04AX01000T1001X iii) Reversal of effect of 300-600 mcg; 12-16 kg: 300 X competitive muscle relaxants mcg; 7-9 kg: 200 mcg; >3 kg:133 Azathioprine 50 mg Tablet iv) Overdosage with other 100 mcg. Doses to be given compounds having via IM/SC admin 30-60 muscarinic action minutes before anaesthesia. v) Organophosphate ii) Adult: 500 mcg every 3-5 poisoning minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body First line therapy for weight. intermediate-2 and high risk iii) Adult 0.6-1.2 mg before or MDS, CMMOL with 10-29% with anticholinesterase blasts with no transplant iv) Adult: 0.6-1 mg IV/IM/SC, option and elderly AML with repeated every 2 hr. 20-30% blasts and v) Adult: 2 mg IV/IM, every multilineage dysplasia. 10-30 minutes until muscarinic effects disappear i) Prophylaxis of rejection in or atropine toxicity appears. organ and tissue transplant In severe cases, dose can be ii) Auto-immune diseases given as often as every 5 iii) Rheumatoid arthritis minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. Child: 20 mcg/kg given every 5-10 minutes. Recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75mg/m2 of body surface area. Injected subcutaneously. Daily for 7 days, followed by a rest period of 21 days (28 day treatment cycle) i) Adult: 1-5 mg/kg/day. Adjust dose according to clinical response and haematological tolerance. Dose may also be given via IV administration. ii) Adult: 1-3 mg/kg/day. Discontinue treatment if there is no improvement after 12 week. iii) Adult: Initially, 1 mg/kg/day given in 1-2 divided doses for 6-8 week,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 24 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY may increase by 0.5 mg/kg every 4 week until response or up to 2.5 mg/kg/day. Maintenance: Reduce dose gradually to achieve the lowest effective dose. Apply twice daily (sensitive134 Azelaic Acid 20% Cream D10AX03000G1001 A* Acne vulgaris skin, once daily for 1st week). XX Treatment should not exceed 6 months CHILD 36 - 45 kg: 400 mg, Treatment of complicated 26 - 35 kg: 300mg, 15 - 25 kg 200 mg, less than 15 kg: 10135 Azithromycin 200 mg/5 ml J01FA10011F1001X A* respiratory tract infections not mg/kg. To be taken daily for Granules X responding to standard 3 days or to be taken as a macrolides single dose on day 1, then half the daily dose on days 2 -5 i) Treatment of complicated respiratory tract infection not responding to standard macrolides ii) Adult treatment of i) 500 mg daily for 3 days uncomplicated genital ii) 1 g as a single dose136 Azithromycin 250 mg Tablet J01FA10011T1001X A* infections due to Chlamydia iii) 1 g weekly X trichomatis or susceptible Neisseria gonorrhoea iii) Prophylaxis against Mycobacterium avium complex in patients with advanced HIV 500 mg IV as a single daily dose for a minimum of two137 Azithromycin 500 mg J01FA10011P4001X A* Only for treatment of severe days followed by 500 mg oral Injection X atypical pneumonia dose as a single daily dose to complete a 7 - 10 days course138 Bacampicillin 400 mg Tablet J01CA06000T1001X B Infections caused by ADULT: 400 mg twice daily. X ampicillin-sensitive gram Severe infection: 800 mg positive& gram negative twice daily. CHILD more than microorganisms 25 kg: 12.5 - 25 mg/kg 12 hourly ADULT: 5 mg 3 times daily. Max: 80 mg daily. CHILD:139 Baclofen 10 mg Tablet M03BX01000T1001 B Spasticity of the skeletal 0.75 - 2 mg/kg daily (more XX muscle than 10 years, maximum: 2.5 mg/kg daily)140 Balanced Salt Solution B05CB10907L5001X A For irrigation during ocular Irrigate as directed X surgery Balanced Salt Solution For irrigation during intraocular surgery especially141 PLUS (fortified with sodium B05CB10905L5001X A in patients with poor cornea Irrigate as directed bicarbonate, glucose & X endothelium and poorly controlled diabetes glutathione)142 Barium Sulphate V08BA01183L8001X B For x-ray examination of the i) Up to 150 ml of a 50% - Suspension X alimentary tract: i) 200% suspension orally Oesophagus ii) Up to 300 ml of a 30% -Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 25 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ii) Stomach and duodenum 200% suspension orally iii) Colon iii) Up to 2 litre of a 30% - 200% suspension orally ADULT & CHILD 2 years and above & 35 kg or more: 20143 Basiliximab 20 mg Injection L04AC02000P3001X A* Prophylaxis of acute organ mg /dose. 2 years or more X rejection in de novo renal but less than 35kg: 10 transplantation. mg/dose. First dose given within 2 hours before start of transplantation and second dose 4th day after transplant 81 mg intravesically once weekly for 6 weeks, followed144 BCG 81 mg/3 ml L03AX03000P3001X A* Superficial bladder cancer by treatments at 3, 6, 12, 18, X and 24 months after initial treatment145 BCG Vaccine Freeze-Dried J07AN01000P4001X C+ For the prevention of 0.1 ml by intradermal Injection X tuberculosis injection. INFANT under 12 months: 0.05 ml Adults: The usual maintenance dose is one to two inhalations (200-400 mcg) twice daily.If needed,the dose can be146 Beclomethasone R03BA01133A2101X B Prophylaxis of asthma increased up to 1600 Dipropionate 100 mcg/dose X especially if not fully mcg/day divided in two to Inhaler controlled by bronchodilators four doses : Children 6-12 years old: One inhalation (200 mcg) two times daily and dose may be increased up to 800 mcg/day in divided two to four doses if necessary. Regular treatment of asthma where use of a combination Beclomethasone product (inhaled Dose recommended for corticosteroid and long-acting patients 18 years and above.147 dipropionate 100mcg and R03AK07986A2101X A/KK beta2 agonist) is appropriate One or two inhalations twice formoterol fumarate X in: daily. The maximum daily dihydrate 6mcg pressurized i.Patients not adequately dose is 4 inhalations daily. inhalation solution controlled with inhaled No need to adjust dose in corticosteroids and 'as elderly patients. There are no needed' inhaled short-acting data available for use in patients with hepatic or renal beta2 agonist or impairment. ii.Patients already adequately controlled on both inhaled corticosteroids and long- acting beta2-agonists ADULT: 1 - 2 puff twice daily.148 Beclomethasone R03BA01133A2102X A/KK Prophylaxis of asthma May increase to 2 puff 2 - 4 Dipropionate 200 mcg/dose X especially if not fully times daily CHILD: 1 puff Inhaler controlled by bronchodilators twice daily. May increase to 1 puff 2 - 4 times dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 26 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Beclomethasone R01AD01133A4101 Prophylaxis and treatment of ADULT and CHILD over 6149 Dipropionate 50 mcg/dose XX A/KK perennial and seasonal years: Apply 100 mcg (2 allergic rhinitis and sprays) into each nostril twice Nasal Spray D08AJ01000G1001X B vasomotor rhinitis daily or 50 mcg (1 spray) into X each nostril 3 - 4 times/day.150 Benzalkonium 0.01% C Prevention and treatment of Maximum 400 mcg daily (8 Cream V07AV00100L9908X B nappy rash sprays). When symptoms X controlled, reduce dose to 50151 Benzalkonium Chloride B Low level disinfectant mcg (1 spray) into each Disinfectant Solution J01CE08702P4001X C suitable for general cleaning nostril twice daily X C and disinfection of hard Wash and dry baby's bottom.152 Benzathine Penicillin 2.4 C surface Apply by spreading the MIU (1.8 g) Injection N04AA01110T1001X B i) Treatment of mild to cream evenly paying X B moderately severe infections particular attention to the fold153 Benzhexol 2 mg Tablet B due to Penicillin G-sensitive of the skin, after every nappy D01AE12952G5001 organisms change Benzoic Acid Compound XX ii) Treatment of syphillis i) Parkinson's disease Cleaning purposes: Dilute 1154 Half Strength (Paed) D01AE12952G5002 ii) Drug induced in 10. Disinfection, use Ointment XX parkinsonism undiluted iii) Dystonias155 Benzoic Acid Compound D08AX00000L5001X i) ADULT: 1.2 mega units IM Ointment X Tinea infections of the skin ii) For syphillis: 2.4 mega Tinea infections of thickened units weekly for 1 - 3 weeks156 Benzoin Compound D10AE01241G3002 skin of palms and soles Tincture XX ADULT: Initially 1 mg daily, Infected skin, lesions, cuts, increase gradually.157 Benzoyl Peroxide 10% Gel D10AE01241G3001 abrasions, wounds and burns Maintenance: 5 - 15 mg daily158 Benzoyl Peroxide 5% Gel XX in 3 - 4 divided doses. (Max Mild to moderate acne 15mg/day)159 Benzydamine HCl 0.15% A01AD02110M2001 vulgaris Solution XX Mild to moderate acne Apply sparingly to affected vulgaris area once or twice daily For relief of painful condition Apply sparingly to affected of the oral cavity area once or twice daily Apply undiluted to the skin 1 or 2 times daily. Duration of therapy, may be weeks to months depending on the infection being treated Apply 1-2 times daily preferably after washing with soap and water Apply 1-2 times daily preferably after washing with soap and water Used as a 30 seconds gargle or rinse, undiluted. ADULT 15 ml. CHILD less 12 years 5-15 ml. Uninterrupted treatment should not be more than 7 daysUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 27 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULTS and CHILDREN Temporary relief of painful OVER 12 YEARS: 2-4 sprays conditions of the mouth and (1-2mg) directly onto the sore/inflamed area and throat including tonsillitis, swallow gently. Repeat every 1 1/2 to 3 hours as sore throat, radiation necessary. CHILDREN 6-12 mucositis, aphthous ulcers, YEARS: 2 sprays (1mg) directly onto sore/ inflamed160 Benzydamine Hydrochloride A01AD02110A4201X A* pharyngitis, swelling, area and swallow gently. 3.0 mg/ml throat spray X redness, inflammatory Repeat every 11/2 to 3 hours conditions, post-orosurgical as necessary. CHILDREN UNDER 6 YEARS: Not and periodontal procedures. recommended. Uninterrupted (For pediatric and treatment should not exceed seven days, unless under otorhinolaringology use. medical supervision Restrict to patients who are After bath, apply over the not able to gargle) whole body, neck down and leave on for 24 hours then161 Benzyl Benzoate 12.5 % P03AX01252L2001X C Scabies and pediculosis, for wash off. Reapply for another Emulsion (Child) X child under 2 years 24 hours, the first repeat application should be within 5162 Benzyl Benzoate 25 % P03AX01000L2002X C+ Scabies and pediculosis days of the initial application, Emulsion (Adult) X a third application may be required in some cases163 Benzylpenicillin 1 mega unit J01CE01702P4001X B i) Infections caused by (600 mg) Injection X susceptible organisms After bath, apply over the ii) Infective endocarditis whole body, neck down and leave on for 24 hours then164 Benzylpenicillin 10,000 S01AA14702D2002X B Eye infection wash off. Reapply for another units/ml Eye Drops X 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases i) Adult: 600mg - 3600mg (1 - 6 mega units) daily, divided into 4 to 6 doses. Higher doses (24 mega units) in divided doses may be given in serious infections such as meningitis. Child 1 month to 12 years old: 100mg/kg/day in 4 divided doses, not exceeding 4g/day; Infants 1 - 4 weeks: 75mg/kg/day in 3 divided doses; Newborn Infants: 50mg/kg/day in 2 divided doses ii) 7.2 to 12g (12 - 20 mega units) maybe given daily in divided doses 1-2 drops every 15 minutes or accordingly to needs of the patientUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 28 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Benzylpenicillin 2,500 S01AA14702D2001X B Eye infection 1-2 drops every 15 minutes165 units/ml (1.5 mg/ml) Eye X or accordingly to needs of the patient Drops i) ADULT: 600 - 1200 mg IM 4 times daily, increased if166 Benzylpenicillin 5 mega J01CE01702P4002X B i) Infections caused by necessary in more serious units (3 g) Injection X susceptible organisms infections. CHILD: 50 - 100 ii) Infective endocarditis mg/kg body weight daily IV in 2 - 4 divided doses ii) ADULT: 7.2 g daily by slow IV infusion in 6 divided doses Beractant Intratracheal R07AA02000L8001X A* Treatment of newborn baby 100 mg/kg (4 ml/kg) body167 Suspension (200 mg X with birth weight of 700 g or weight intratracheally up to 4 greater undergoing doses in 1st 48 hr. Doses phospholipids in 8 ml vial) mechanical ventilation for should not be given more respiratory distress frequently than 6 hrly. To be syndrome, whose heart rate administered as soon as and arterial oxygenation are possible. continuously monitored i) Meniere's Syndrome as defined by the following core168 Betahistine Dihydrochloride N07CA01110T1002X A/KK symptoms: - Vertigo (with Given in doses of 8 to 16 mg 16 mg Tablet X nausea/vomiting). - Hearing orally 3 times daily (total 24 loss (Hardness of hearing). - to 48 mg/day) preferably with Tinnitus (ringing in the ears) food. CHILD not ii) Symptomatic treatment of recommended vestibular vertigo i) Meniere's Syndrome as defined by the following core symptoms: - Vertigo (with169 Betahistine Dihydrochloride N07CA01110T1003X A* nausea/vomiting). - Hearing 24-48mg in divided doses 24 mg Tablet X loss (Hardness of hearing). - daily Tinnitus (ringing in the ears) ii) Symptomatic treatment of vestibular vertigo i) Meniere's Syndrome as170 Betahistine Dihydrochloride N07CA01110T1001X A/KK defined by the following core Given in doses of 8 to 16 mg 8 mg Tablet X symptoms: - Vertigo (with orally 3 times daily (total 24 nausea/vomiting). - Hearing to 48 mg/day) preferably with loss (Hardness of hearing). - food. CHILD not Tinnitus (ringing in the ears) recommended ii) Symptomatic treatment of vestibular vertigo171 Betamethasone 0.5 mg H02AB01000T1001X A Suppression of inflammatory 0.5 - 9 mg daily in divided Tablet X and allergic disorders, doses. CHILD: 0.5 - 7.5 congenital adrenal mg/m2/day divided every 6 - hyperplasia, cerebral 12 hours oedema172 Betamethasone 17-Valerate D07AC01256G1001 B Eczemas, prurigo nodularis, Apply sparingly to affected 0.01-0.05% Cream XX limited psoriasis in area 2 - 3 times daily then appropriate in sites reduced to once daily when improvement occurs173 Betamethasone 17-Valerate D07AC01256G5001 B Eczema, prurigo nodularis, Apply sparingly to affected 0.01-0.05% Ointment XX limited psoriasis in area 2 - 3 times daily then appropriate in sites reduced to once daily when improvement occursUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 29 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY174 Betamethasone 17-Valerate D07AC01256G1002 A Eczemas, prurigo nodularis, Apply sparingly to affected 0.1% Cream XX psoriasis (excluding area 2 - 3 times daily then widespread plaque psoriasis) reduced to once daily when improvement occurs175 Betamethasone 17-Valerate D07AC01256G5002 A Eczema, prurigo nodularis, Apply sparingly to affected 0.1% Ointment XX psoriasis (excluding area 2-3 times daily then widespread plaque psoriasis) reduced to once daily when improvement occurs176 Betamethasone Disodium S03BA03162D1001X B Non-infected inflammatory Apply 2 - 3 drops every 2 - 3 Phoshate 0.1% Ear Drops X conditions hours, reduce frequency when relief obtained177 Betamethasone Disodium S03BA03162D1002X B Non-infected inflammatory Apply 2 - 3 drops every 2 - 3 Phoshate 0.5% Ear Drops X conditions hours, reduce frequency when relief obtained178 Betamethasone Disodium S01BA06162D2001X A Non-infected inflammatory 1 - 2 drops every 1 - 2 hours Phosphate 0.1% Eye Drops X conditions of the eyes until controlled then reduce frequency Betamethasone Disodium S01BA06162G5101 A Non-infected inflammatory 2 - 4 times daily or at night179 Phosphate 0.1% Eye XX conditions of the eyes when used with eye drops Ointment Betamethasone Disodium S03CA06991D1001 B Apply 2 - 3 drops 3 - 4 times180 Phosphate and Neomycin XX Allergic dermatosis in the ear daily, reduce frequency when Sulphate 0.5% Ear Drops relief obtained Betamethasone Disodium S01CA05991D2001 A Infected inflammatory 2 - 3 drops every 2 - 3 hours181 Phosphate and Neomycin XX conditions of the eyes Sulphate Eye Drops Betamethasone Sodium H02AB01162P3001X B Pre-operative and in serious Usual intravenous doses are182 Phosphate 4 mg/ml X trauma or illness, shock, as up to 9 mg/day of the sodium adjunctive therapy in phosphate salt only. CHILD: Injection rheumatoid disorders, ocular, IM: 0.5 - 7.7 mg base/m2/day dermatologic and respiratory divided every 6 - 12 hours. allergic and inflammatory ADOLESCENT and ADULT, states IM: 0.6 - 9 mg divided every 12 - 24 hours183 Betaxolol 0.25% Eye S01ED02110D2001 Chronic open-angle One to two drops in the Suspension XX A glaucoma, ocular affected eye(s) twice daily hypertension 50 mg once daily (morning or evening), with or without food. Take on the same time Advanced prostate cancer in each day. Adult: When used184 Bicalutamide 50 mg Tablet L02BB03000T1001X A* combination with LHRH with gonadorelin analogue: X analogue therapy or surgical Usual dose: 50 mg once castration. daily. May be started with or at least 3 days before starting gonadorelin analogue therapy. Lowering of intraocular pressure in patients with Bimatoprost 0.03% S01EE03000D2001X open-angle glaucoma and Ophthalmic Solution X ocular hypertension who are 1 drop in affected eye(s)185 A* intolerant of other intraocular once daily at evening pressure lowering medications or insufficiently responsive to anotherUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 30 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY intraocular pressure lowering medication i) ADULT and CHILD over 10 years: 10 mg, CHILD less Bisacodyl 10 mg i) Constipation than 10 years 5 mg insert Suppository A06AB02000S2002X ii) Bowel preparation for rectally186 X C radiological procedures and ii) ADULT 10-20 mg, CHILD surgery over 4 years 5 mg the following morning before procedures insert rectally i) ADULT and CHILD over 10 years: 10 mg, CHILD less i) Constipation than 10 years 5 mg insert187 Bisacodyl 5 mg Suppository A06AB02000S2001X C ii) Bowel preparation for rectally X radiological procedures and ii) ADULT 10-20 mg, CHILD surgery over 4 years 5 mg the following morning before procedures insert rectally i) ADULT and CHILD over 10 years 5-10 mg, CHILD 4-10188 Bisacodyl 5 mg Tablet A06AB02000T1001X C i) Constipation years 5 mg. To be taken at X ii) Bowel preparation for night for effect on the radiological procedures and following morning surgery ii) ADULT 10-20 mg the night before procedures, CHILD over 4 years 5 mg the night before procedures As a mild antiseptic for Bismuth Subnitrate, wounds and abscesses.189 Iodoform and Liquid R01AX30984G6001 B Sterile gauze impregnated As directed for local Paraffin Paste XX with paste for packing application cavities after otorhinological surgery Bisoprolol Fumarate 2.5 mg C07AB07000T1001X Treatment of stable moderate to severe congestive cardiac 1.25 mg once daily to 5 - 10190 Tablet X B failure in addition to ACEI's mg daily and diuretics Treatment of stable moderate191 Bisoprolol Fumarate 5 mg C07AB07000T1002X B to severe congestive cardiac 1.25 mg once daily to 5 - 10 Tablet X failure in addition to ACEI's mg daily and diuretics 15 - 30 mg weekly in divided192 Bleomycin HCl 15 mg L01DC01110P4001X A Squamous cell carcinoma, doses or 10 - 20 mg/m2 once Injection X germ cell tumours, or twice weekly or 10 mg/m2 lymphomas. Routes: SC, IM, slow bolus in 15 minutes D1 IV (either as bolus or as and D15. Total infusion over 24 hours), intra- dosage:should not exceed arterial, intra-pleural 300 mg. CHILD: 10 - 15 mg/m2 over 6 hours every 3 - 4 weeks193 Boric Acid with Spirit 2% S02AA03000D1001X C Perforated eardrum 3 drops instilled into affected w/v Ear Drops X ear 3 - 4 times daily i) Treatment of multiple 1.3 mg/ m2/dose given as IV194 Bortezomib 3.5 mg Injection L01XX32000P3001X A* myeloma in patient who have bolus injection twice weekly X received at least one prior for two weeks (days 1, 4, 8, therapy. and 11) followed by a 10- dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 31 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ii) For use in combination rest period (days 12-21). At with conventional therapy for least 3 days should elapse the treatment of previously between consecutive doses untreated multiple myeloma of bortezomib patients who are not eligible for haematopoietic stem cell transplantation. For the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class III Initially 62.5 mg bd for 4 C02KX01000T1001X or IV symptoms, to improve weeks, then increase to the195 Bosentan 125 mg tablet X A* exercise ability and decrease maintenance dose of 125 mg the rate of clinical worsening bd (To be used by those who are trained and specialized in treating and managing PAH) Lowering of intraocular196 Brimonidine Tartrate 0.15% S01EA05123D2001X A* pressure in patients with 1 drop in the affected eye(s) Ophthalmic X open-angle glaucoma or 3 times daily ocular hypertension Adult: Initially, 6-18 mg daily in divided doses. Doses up to197 Bromazepam 3 mg Tablet N05BA08000T1002X A Anxiety disorders 60 mg daily have been used. X Elderly: Max initial dose: 3 mg daily Secretolytic therapy in acute and chronic 4 to 8 mg SC, IM or IV 2 - 3 Bromhexine HCl 4 mg/2 ml R05CB02110P3001 bronchopulmonary diseases times daily (maximum 24mg/198 Injection XX A associated with abnormal day). Elderly: Max initial mucous secretion and dose: 3 mg daily. impaired mucous transport199 Bromhexine HCl 4 mg/5 ml R05CB02110L1001X B Secretolytic therapy in acute 1) Adults: 10 ml three times a Elixir X and chronic day.Can increase up to 15 ml bronchopulmonary diseases four times a day. associated with abnormal 2)Children 5 to 12 years : 5 mucous secretion and ml four times a day impaired mucous transport 3)Children 2 to 5 years: 5 ml two times a day200 Bromhexine HCl 8 mg R05CB02110T1001X B Secretolytic therapy in acute ADULT and CHILD more Tablet X and chronic bronchopulmonary diseases than 12 years : 8 mg 3 times associated with abnormal daily, 6 - 12 years : 4 mg 3 mucous secretion and impaired mucous transport times daily, 2 - 6 years : 4 mg 2 times daily i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg201 Bromocriptine Mesilate 10 G02CB01196T1003 i) Hypogonadism or daily mg Tablet XX A/KK Galactorrhoea ii) 1.25 - 2.5 mg at bedtime for 3 days and may be ii) Acromegaly increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 32 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) Initially 1 - 1.25 mg at202 Bromocriptine Mesilate 2.5 G02CB01196T1001 i) Hypogonadism or bedtime increased gradually, mg Tablet XX A/KK Galactorrhoea usual dose: 7.5 mg daily in divided doses. Max 30 mg ii) Acromegaly daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg203 Bromocriptine Mesilate 5 G02CB01196T1002 i) Hypogonadism or daily mg Tablet XX A/KK Galactorrhoea ii) 1.25 - 2.5 mg at bedtime for 3 days and may be ii) Acromegaly increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses204 Budesonide 1 mg/2 ml R03BA02000A3002X B Maintenance treatment of ADULT: Initially 1 - 2 mg Nebuliser Solution X asthma as prophylactic twice daily. CHILD 3 months therapy especially if not fully - 12 years of age : 500 mcg - controlled by bronchodilators 1 mg. Maintenance dose : half of the above doses ADULT: 200 - 1600 mcg daily in 2 - 4 divided doses. Maintenance treatment of Maintenance with twice daily205 Budesonide 100 mcg/dose R03BA02000A2101X B asthma as prophylactic dosing. CHILD more than 7 Inhaler X therapy especially if not fully years 200 - 800 mcg, 2 - 7 controlled by bronchodilators years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses Budesonide 160 mcg and R03AKO7989A2101 A/KK i) Regular treatment of Asthma Maintenance therapy206 Formoterol 4.5 mcg XX asthma where use of a Adult ≥18 yr 160 mcg to 320 combination (inhaled mcg bd. Some patients may Inhalation corticosteroid and long-acting require up to a max of 640 beta2-agonist) is appropriate: mcg bd. Adolescent 12-17 yr - Patients not adequately 160 mcg to 320 mcg bd. controlled with inhaled Childn 6-11 yr 160 mcg bd, corticosteroids and 'as <6 yr Not recommended. Maintenance & relief Adult needed' inhaled short-acting beta2-agonists. or ≥18 yr 320 mcg/day either as - Patients already adequately 160 mcg bd or 320 mcg controlled on both inhaled either morning or evening. corticosteroids and long- For some patients a acting beta2-agonists. maintenance dose of 320 ii) Symptomatic treatment of mcg bd may be appropriate. patients with severe COPD Patients should take 160 mcg (FEV1 <50% predicted additional inhalation as normal) and a history of needed in response to repeated exacerbations, who symptoms. If symptoms have significant symptoms persist after a few minutes, despite regular therapy with an additional inhalation long-acting bronchodilators. should be taken. Not more than 960 mcg should beUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 33 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Childn & adolescent <18 yr Not recommended. COPD Adult ≥18 yr 320 mcg bd. ADULT: 200 - 1600 mcg daily in 2 - 4 divided doses. R03BA02000A2102X Maintenance treatment of Maintenance with twice daily Budesonide 200 mcg/dose X asthma as prophylactic dosing. CHILD more than 7207 Inhalation B therapy especially if not fully years 200 - 800 mcg, 2 - 7 controlled by bronchodilators years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses Asthma; Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. i) Regular treatment of Adolescent 12-17 yr 160 mcg asthma where use of a to 320 mcg bd. Children 6-11 combination (inhaled yr 160 mcg bd, <6 yr Not corticosteroid and long-acting recommended. Maintenance beta2-agonist) is & relief: Adult ≥18 yr 320 appropriate:- mcg/day either as 160 mcg - Patients not adequately bd or 320 mcg either morning controlled with inhaled or evening. For some corticosteroids and 'as patients a maintenance dose needed' inhaled short-acting of 320 mcg bd may be Budesonide 320 mcg and R03AK07989A2102X beta2-agonists. or appropriate. Patients should208 Formoterol 9 mcg Inhalation X A/KK - Patients already adequately take 160 mcg additional controlled on both inhaled inhalation as needed in corticosteroids and long- response to symptoms. If acting beta2-agonists. symptoms persist after a few ii) Symptomatic treatment of minutes, an additional patients with severe COPD inhalation should be taken. (FEV1 <50% predicted Not more than 960 mcg normal) and a history of should be taken on any repeated exacerbations, who single occasion. A total daily have significant symptoms dose of more than 1280 mcg despite regular therapy with is not normally needed, long-acting bronchodilators. however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should beUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 34 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY reassessed & their maintenance therapy reconsidered. Children & adolescent less than 18 yr: Not recommended. COPD; Adult more than or equal to 18 yr: 320 mcg bd.209 Budesonide 500 mcg/2 ml R03BA02000A3001X B Maintenance treatment of ADULT: Initially 1 - 2 mg Nebuliser Solution X asthma as prophylactic twice daily. CHILD 3 months therapy especially if not fully - 12 years of age : 500 mcg - controlled by bronchodilators 1 mg. Maintenance dose : half of the above doses ADULT and CHILD 6 years and older. Rhinitis: 2 spray210 Budesonide 64mcg Nasal R01AD05000A4103 A Seasonal allergic, perennial into each nostril once daily in Spray XX rhinitis and nasal polyposis the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily Bumetanide 0.5 mg/ml C03CA02000P3001 IV injection: 1 - 2 mg Injection XX Oedema used in furosemide repeated after 20 mins. IV211 A* allergic patient infusion: 2 - 5 mg over 30 - 60 mins212 Bumetanide 1 mg Tablet C03CA02000T1001X A* Oedema used in furosemide 1 mg in the early evening. Up X allergic patient to 5 mg daily in severe cases213 Bupivacaine 0.125% N01BB01110P3004X A Epidural analgesia for Infuse at 6 - 15 ml/hour. Not Epidural Injection X postoperative pain relief. to exceed 2 mg/kg in a single dose.214 Bupivacaine 0.5 % Heavy N01BB01110P3003X A Used for spinal anaesthesia ADULT: 2 - 4 ml. Not to Injection X exceed 2 mg/kg in a single dose Regional nerve block or epidural block: 15 - 30 ml. For peripheral sympathetic Nerve block of finger or toe: 2215 Bupivacaine 0.5 % Injection N01BB01110P3002X B nerve and epidural (excluding - 6 ml. Maximum: 2 mg/kg X caudal) anaesthesia and body weight in any 4 hours obstetrics anaesthesia period, equivalent to 25 - 30 ml in adults of average weight 10 - 40 ml (0.25 %) or Bupivacaine 0.5 % with N01BB51975P3001X B Regional nerve block or maximum : 2 mg/kg body216 Adrenaline 1:200,000 X epidural block. weight in any 4 hours period, equivalent to 25 - 30 ml of Injection 0.5% solutionUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 35 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE N02AE01110M7001 CATEGORY Once weekly transdermal XX Treatment of non-malignant patch/for hospital use only. Patient aged 18 years and N02AE01110M7003 pain of moderate intensity over. Initial dose: 5 mcg/hr XX when an opioid is necessary For elderly: Renal impairment. No special dose for obtaining adequate adjustments necessary in Buprenorphine 10mcg/hr analgesia. Not suitable for patients with renal217 transdermal patch A* the treatment of acute pain. impairment Hepatic impairment Patients with Restrictions: For elderly hepatic insufficiency should patients or patients with be carefully monitored during the treatment with comorbidities/difficult to buprenorphine patch. Alternate therapy should be swallow considered. Patch should be used with cautions in severe Treatment of non-malignant hepatic impairment patient Once weekly transdermal pain of moderate intensity patch/for hospital use only. when an opioid is necessary Patient aged 18 years and over. Initial dose: 5 mcg/hr for obtaining adequate For elderly: Renal impairment. No special dose218 Buprenorphine 5mcg/hr A* analgesia. Not suitable for adjustments necessary in transdermal patch the treatment of acute pain. patients with renal impairment Hepatic Restrictions: For elderly impairment Patients with hepatic insufficiency should patients or patients with be carefully monitored during comorbidities/difficult to the treatment with buprenorphine patch. swallow Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient i) ADULT: Initial: 2 - 4 mg daily. Maintenance: 0.5 - 2 mg daily. Stop when white blood cell less than 20 x i) Chronic myeloid leukaemia 109/L. CHILD: 60 mcg/kg (CML) and other body weight daily219 Busulfan 2 mg Tablet L01AB01000T1001X A myeloproliferative diseases ii) CHILD: Induction 60 X ii) Haemopoietic stem cell mcg/kg body weight daily transplant (HSCT)- refer to (maximum 4 mg) if specific protocols leucocytes more than 20,000/mm3 and platelets more than 100,000/mm3. Maintenance 10 - 30mcg/kg (maximum 2 mg daily)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 36 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY For use in combination with cyclophosphamide as a220 Busulfan 6 mg/ml Injection L01AB01000P3001X A* conditioning regimen prior to 0.8 mg/kg of ideal body X allogeneic hematopoietic weight or actual body weight, stem cell transplantation whichever is lower via central (HSCT) for chronic venous catheter as a 2-hour myelogenous leukemia in infusion on the basis of every selected cases with high risk 6 hours for 4 days, for a total of liver toxicity and of 16 doses. For obese or intolerance to oral busulfan. severely obese patients, IV To be prescribed by Busulfan should be paediatric oncologist and administered based on consultant haematologist adjusted ideal body weight trained in transplant only.221 Cabergoline 0.5 mg Tablet G02CB03000T1001 A* i) Treatment of i) 0.5mg per week given in 1 XX hyperprolactinaemic or 2 (one-helf of one 0.5mg disorders tablet) doses per week ii) Prevention of puerperal ii) HIV mothers only: Prevent lactation and suppression of lactation 2 tab first day after lactation in HIV infected delivery. Interruption of mothers only laction: 0.25mg 12 hourly for 2 days Soothes and relieves nappy rashes, prickly heat, minor222 Calamine Cream D04AX00000G1001 C+ skin irritations, insect bites Apply to the affected area as XX and sunburn, Pruritic skin required, 1-3 times daily conditions. Soothes and relieves nappy223 Calamine Lotion D04AX00000L8001X C+ rashes, prickly heat, minor Apply to the skin as required X skin irritations, insect bites and allow to dry, 1-3 times and sunburn, Pruritic skin daily conditions. Soothes and relieves nappy224 Calamine with 0.25 - 0.5% D04AX00952L6001X C rashes, prickly heat, minor Apply to the skin as required Menthol Lotion X skin irritations, insect bites and allow to dry, 1 - 3 times and sunburn, Pruritic skin daily conditions.225 Calamine with 0.5% Phenol D04AX00952G1001 C For use as a mild astringent Apply to the affected area as Cream XX required226 Calamine with 2 - 6% D04AX00952L6002X C Acne vulgaris Apply to the skin as required Precipitated Sulphur Lotion X and allow to dry, 1 - 3 times daily ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose227 Calcipotriol 50 mcg/g D05AX02000G1001 A* Only for the treatment of should not exceed 100 g. Cream XX Psoriasis Vulgaris CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weeklyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 37 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT Apply to the affected228 Calcipotriol 50 mcg/g D05AX02000G5001 A* Only for the treatment of skin lesions twice daily. Ointment XX Psoriasis Vulgaris Maintenance therapy may be achieved with less frequent229 Calcipotriol 50 mcg/ml D05AX02000L9901X A* Only for the treatment of application. The weekly dose Scalp Solution X Psoriasis Vulgaris should not exceed 100 g. CHILD over 6 years, apply Calcipotriol Hydrate 50 twice daily. 6-12 years mcg/g & Betamethasone D05AX52952G5001 maximum 50gm weekly, over230 Dipropionate 0.5 mg/g XX A* Resistant plaque psoriasis 12 years maximum 75gm weekly Ointment Apply to scalp twice daily. Maximum 60 mL weekly.231 Calcipotriol monohydrate 50 D05AX52952G3001 Topical treatment of scalp Apply once daily up to 4 mcg/g and Betamethasone XX A* and non-scalp plaque weeks with maximum weekly dipropionate 0.5 mg/g Gel dose of 100g and maximum psoriasis vulgaris in adults treatment area 30% of body surface232 Calcitonin (synthetic H05BA01000P3002X A* Acute hypercalcaemia Should be applied to affected Salmon) 100 IU Injection X areas once daily. The recommended treatment Calcitonin (Synthetic H05BA01000A4101X A* Osteoporosis period is 4 weeks for scalp233 Salmon) 200 IU Nasal X areas and 8 weeks for non- scalp areas. The body Spray surface area treated with calcipotriol containing234 Calcitonin (Synthetic H05BA01000P3001X A* Acute hypercalcaemia products should not exceed Salmon) 50 IU Injection X 30% and maximum dose should not exceed 15g or 100g/ week 5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed. 200 units daily 5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 38 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 0.25 mcg 2 times daily ii) Initial dose 0.25 mcg. In235 Calcitriol 0.25 mcg Capsule A11CC04000C1001 A/KK i)Established patients with normal or only XX postmenopausal slightly reduced serum osteoporosis calcium levels, doses of 0.25 ii) Renal osteodystrophy in mcg every other day is patients on haemodialysis sufficient iii)Hypoparathyroidism and iii) 0.25 mcg/day given in the rickets morning iv)Secondary iv) ADULT and CHILD 3 hyperparathyroidism in renal years and older : Initially 0.25 failure mcg/ml. CHILD less than 3 years : 10 to 15 ng/kg/day236 Calcitriol 1 mcg/ml Injection A11CC04000P3001 A* Management of Initially dose, depending on XX hypocalcaemia and/or severity, 1 mcg (0.02 mg/kg) secondary to 2 mcg 3 times weekly, hyperparathyroidism in approximately every other patients undergoing chronic day renal dialysis237 Calcitriol 2 mcg/ml Injection A11CC04000P3002 A* Management of Initially dose, depending on XX hypocalcaemia and/or severity, 1 mg (0.02 mg/kg) secondary to 2 mg 3 times weekly, hyperparathyroidism in approximately every other patients undergoing chronic day renal dialysis ADULT: Typical oral doses of calcium carbonate range from about 3gm to 7gm daily in divided dose. US National238 Calcium Carbonate 500 mg A12AA04121C1001X B i) Elemental calcium Foundation suggest the Capsule X supplementation ii) calcium-based phosphate Phosphate binder in chronic binder should not exceed renal failure patients 1.5gm daily in those with kidney failure. CHILD (12-18 years old): 1.25gm 3 or 4 times daily with or before meals and adjusted as necessary. To be used only for elemental calcium239 Calcium Carbonate 500 mg A12AA04121T1001X B supplementation and Initial 2.5 g daily and Tablet X phosphate binding activity in increased up to 17 g daily patients with chronic renal failure The maximum infusion rate Calcium Chloride Dihydrate, depends on the needs of the Sodium Chloride, Replacement of extracellular patient in fluid replacement fluid losses in the case of and electrolytes, patient’s Magnesium Chloride B05BB01905P6002X isotonic dehydration, where weight, clinical condition, and Hexahydrate, Sodium X acidosis is present or biological status. Adults,240 Acetate A imminent. elderly, adolescents:500ml- 3L/24hr. Babies, children: Trihydrate,Potassium Chloride, and Malic Acid Solution 20ml to 100ml/kg/24 hr.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 39 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY IM (Lead encephalopathy): 1000 mg/m (2)/day IM in divided equal doses 8 to 12 hours apart, for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of241 Calcium Disodium Edetate V03AB03999P3001X A Lead Poisoning therapy, if indicated. Do not 200 mg Injection X exceed the recommended daily dosage. IV: 1000 mg/m (2)/day administered IV over 8 to 12 hours for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. i) 1-2 g (2.25-4.5 mmol). CHILD 50 mg/kg242 Calcium Gluconate 10% A12AA03000P3001X B i)Acute hypocalcaemia ii) ADULT 1g (2.2 mmol) by Injection X ii)Hypocalcaemic tetany slow IV injection followed by iii)Cardiac resuscitation continuous infusion of 4 g (8.8 mmol) daily iii) IV or intracardiac injection, 10 ml243 Calcium Lactate 300 mg A12AA05125T1001X C For prophylaxis of calcium ADULT 1-5 g daily in divided Tablet X deficiency and treatment of doses chronic hypocalcaemia 15 - 30g daily in 2-3 divided244 Calcium Polystyrene V03AE01999F2101X A Hyperkalemia resulting from doses. Each dose should be Sulphonate Powder X acute or chronic renal failure suspended in 30 - 50ml of water and administered orally245 Capecitabine 150 mg Tablet L01BC06000T1002X A* i) Metastatic breast cancer in i) & ii) 1250 mg/m2 twice X elderly and poor performance daily (morning and evening) status patients and refractory for 2 weeks, every 21 days. to taxanes. iii) Recommended for a total ii) Metastatic colon cancer, of 24 weeks (8 cycles of 2 first line in elderly and poor weeks of drug administration performance status patients. and 1 week rest period. iii) Colon cancer, adjuvant iv) In combination with a therapy for stage III (Duke's platinum on day 1, give Stage C) following surgery. capecitabine 1250 mg/m2 iv) First line treatment of twice daily for 14 days. patients with advanced Repeated every 3 weeks for gastric cancer in combination 8 cycles or optimum number with a platinum-based of cycles regimen i) Metastatic breast cancer in i) & ii) 1250 mg/m2 twice elderly and poor performance daily (morning and evening) status patients and refractory for 2 weeks, every 21 days to taxanes iii) Recommended for a total ii) Metastatic colon cancer, of 24 weeks (8 cycles of 2246 Capecitabine 500 mg Tablet L01BC06000T1001X A* first line in elderly and poor weeks of drug administration X performance status patients and 1 week rest period iii) Colon cancer, adjuvant iv) In combination with a therapy for stage III (Duke's platinum on day 1, give Stage C) following surgery iv) capecitabine 1250 mg/m2 First line treatment of twice daily for 14 days.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 40 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY patients with advanced Repeated every 3 weeks for gastric cancer in combination 8 cycles or optimum number with a platinum-based of cycles regimen i) Initially 12.5 mg twice daily. Maintenance: 25-50 mg 2 - 3 times daily, may be increased to maximum 450 mg/day in divided doses ii) Initially 6.25 - 12.5 mg 3 times daily, increase after247 Captopril 25 mg Tablet C09AA01000T1002X B i) Hypertension several days to 25 - 50 mg 3 X ii) Congestive heart failure times daily iii) Post-myocardial infarction iii) Start 3 days after MI iv) Diabetic nephropathy Initially 6.25 mg daily, gradually increased to 37.5 mg daily in divided doses. May increase after several week to 150 mg/day in divided doses if needed and tolerated iv)75 - 100 mg daily in divided dose.248 Carbachol 0.01% S01EB02100D2001X A For intraocular use for miosis Instill no more than 0.5 ml Intraocular Solution X during surgery gently into the anterior chamber ADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. CHILD: 10-249 Carbamazepine 100 mg/5 N03AF01000L9001X A Epilepsy 15 years: 0.6-1 g daily; 5-10 ml (2% w/v) Syrup X years: 400-600 mg daily; 1-5 years: 200-400 mg daily; less than or equal to 1 year: 100- 200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses. Max: Adult: 1.6 g daily ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals Carbamazepine 200 mg CR N03AF01000T5001X until optimal response is obtained. Maximum 1.6250 Tablet X A Epilepsy g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of ageUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 41 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1 year: 100 - 200 mg daily; 1 - 5 yrs: 200 - 400 mg daily; 5 - 10 years: 400 - 600 mg daily; 10 - 15 years: 0.6 - 1 g daily251 Carbamazepine 200 mg N03AF01000T1001X B i) Epilepsy ii) The initial dosage of 200 to Tablet X ii) Trigeminal neuralgia 400mg should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. In elderly patients, an initial dose of 100mg twice daily is recommended. ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is252 Carbamazepine 400 mg CR N03AF01000T5002X A Epilepsy obtained. Maximum 1.6 Tablet X g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age Contact irritant dermatitis, Apply sparingly and rub into253 Carbamide (Urea) 10 % D02AE01000G1001 B infantile eczemas, acute and affected area 2 - 3 times daily Cream XX chronic allergic eczemas, and when required after icthyosis, hyperkeratotic cleansing skin A single IV dose of 100mcg (1ml) is adminitered by bolus Prevention of uterine atony injection, slowly over254 Carbetocin 100 mcg/ ml H01BB03000P2001X A* and postpartum hemorrhage 1minute, only when delivery Injection X following elective cesarean of the infant has been section under epidural or completed by caesarean spinal anaesthesia section under epidural or spinal anaesthesia, before or after delivery of the placenta. ADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to255 Carbimazole 5 mg Tablet H03BB01000T1001X B Hyperthyroidism 20mg daily. CHILDREN > 6 X years: Initially 15mg daily in divided doses. CHILDREN 1- 6 years: Initially 7.5mg daily in divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 42 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY256 Carboplatin 150 mg L01XA02000P4001X Adult solid tumours, 360 - 400 mg/m2 BSA, by IV Injection X A* paediatric tumours. Salvage infusion over 15 mins to 1 therapy for lymphoma hour on Day 1 every 4257 Carboplatin 450 mg L01XA02000P4002X A* weeks. Alternatively, Injection X A* Adult solid tumours, prescription may be based on A* paediatric tumours. Salvage Area Under Curve (AUC)258 Carboprost Tromethamine G02AD04999P3001 therapy for lymphoma calculations. CHILD: 500-600 250 mcg Injection XX A/KK mg/m2 over 1 hour once A/KK Postpartum haemorrhage every 3 weeks. Salvage Cardioplegia solution B05XA16934P3001X refractory to oxytocin regimes in lymphomas - refer containing Potassium X to specific protocols. Starting259 Chloride, Magnesium For myocardial dose in renal impairment, chloride & Procaine HCl C07AG02000T1002 preservation(prevent please refer to product insert. Injection XX myocardial damage) during cardiac surgery 360 - 400 mg/m2 BSA, by IV260 Carvedilol 25 mg Tablet C07AG02000T1001 infusion over 15 mins to 1 XX Treatment of stable moderate hour on Day 1 every 4261 Carvedilol 6.25 mg Tablet to severe congestive cardiac weeks. Alternatively, failure in addition to ACEI's prescription may be based on and diuretics Area Under Curve (AUC) calculations. CHILD: 500-600 Treatment of stable moderate mg/m2 over 1 hour once to severe congestive cardiac every 3 weeks. Salvage failure in addition to ACEI's regimes in lymphomas - refer and diuretics to specific protocols. Starting dose in renal impairment, please refer to product insert. Initially 250 mcg deep IM inj. The dose may be repeated at intervals of 15-90 min if necessary. Max total dose: 2 mg. Dilute 20 ml to 1 L of Ringer solution (cooled to 2-8 °C prior to use). Initial rapid instillation into aortic root at 300 ml/m² body surface area/min for 3 minutes. Should myocardial activity persist or recur instill at 300ml/m² body surface area/min for 2 minutes 3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg: 25 mg bid; >85 kg: 50 mg bid. 3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg:Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 43 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 25 mg bid; >85 kg: 50 mg bid. i) Confirmed systemic fungal infection in patients who are refractory or intolerant to other fungal therapies. ii) For pediatric patient (12262 Caspofungin Acetate 50 mg J02AX04122P4001X A* month and older) for the i) Invasive aspergillosis & Injection X following indications : invasive candidiasis: ADULT: a) Empirical therapy for Initially, 70 mg infused over 1 presumed fungal infections in hour followed by subsequent febrile, neutropenic patients doses of 50 mg/day. b) Treatment of invasive Oesophageal candidiasis: candidiasis, including ADULT: 50 mg by slow IV candidemia and the following infusion over approximately 1 Candida infections ; intra- hour abdominal abscesses, ii) For all indications, a peritonitis and pleural space loading dose of 70mg/m2 on infections D1 followed by maintenance c) Treatment of esophageal dose of 50mg/m2 od. candidiasis d) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B)263 Caspofungin Acetate 70 mg J02AX04122P4002X A* For adult and pediatric i) Invasive aspergillosis & patient (12 month and older) invasive candidiasis: ADULT: Injection X for the following indications: Initially, 70 mg infused over 1 a) Treatment of invasive hour followed by subsequent candidiasis, including doses of 50 mg/day. candidemia and the following Oesophageal candidiasis: Candida infections ; intra- ADULT: 50 mg by slow IV abdominal abscesses, infusion over approximately 1 peritonitis and pleural space hour daily infections ii) Child (12months to 17 b) Treatment of invasive years) : For all indication) A Aspergillosis in patients who single 70mg/m2 loading dose are refractory to or intolerant (not to exceed an actual dose of others therapy (eg : of 70mg) by slow IV infusion Amphotericin B) over 1hour; followed by c) Treatment of esophageal 50mg/m2 (not to exceed an candidiasis (need to follow actual dose of 70mg) the current indications) Infections caused by264 Cefaclor 125 mg/5 ml J01DC04000F2101X A susceptible organisms CHILD :> 1 mth: 20 mg/kg Suspension X including Staphylococcus daily in 3 divided doses, aureus and H. influenzae, increased to 40 mg/kg daily if treatment of sinusitis and necessary, <1 yr: 62.5 mg tid, infections involving the 1-5 yr: 125 mg tid, >5 yr: 250 respiratory tract, skin and mg tid. Maximum: 1 g daily skin structure, bone and joint, and urinary tractUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 44 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY265 Cefaclor 375 mg MR Tablet J01DC04010T5001X A i) Adult pharyngitis, tonsillitis, i) 375 mg twice daily X skin& soft tissue infections ii) 375 mg or 500 mg twice ii) Bronchitis daily iii) Pneumonia iii) 750mg twice daily iv) Lower UTI iv) 375mg twice daily or 500 mg once daily266 Cefaclor 500 mg Capsule J01DC04000C1002X A Infections caused by ADULT: 250 mg 3 times daily X susceptible organisms for 10 days. For severe including Staphylococcus infections, double the aureus and H. influenzae, dosage. Maximum: 4 g daily. treatment of sinusitis and CHILD :> 1 mth: 20 mg/kg infections involving the daily in 3 divided doses, respiratory tract, skin and increased to 40 mg/kg daily if skin structure, bone and joint, necessary, <1 yr: 62.5 mg tid, and urinary tract 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Maximum: 1 g daily267 Cefazolin Sodium 1 g J01DB04520P3001X A Infection caused by ADULT: Uncomplicated Injection X cefazolin-sensitive infections: 500 - 1000 mg 2 - microorganism, infection of 3 times daily. Moderately the respiratory tract, severe and severe infections: urogenital tract, skin and soft 500 - 1000 mg 3 - 4 times tissue, bile duct, bones and daily. Severe life-threatening joint, endocarditis, systemic infections: 1 - 1.5 g 4 times septic infection, peri- daily. Rarely, dose up to 12 g operative/ surgical daily. CHILDREN >1 month: prophylaxis 25-50mg/kg/day in 3-4 divided dose Febrile neutropenia, ADULT: 1 - 2 g twice daily for septicaemia, lower most infections. For severe268 Cefepime 1 g Injection J01DE01110P4002X A* respiratory tract infection, infections including febrile X urinary tract infection, skin neutropenia: 2 g 3 times and skin structure infections, daily. CHILD:2 mth - 16 yr: gynaecologic and intra- ≤40 kg: 50 mg/kg every 8-12 abdominal infections hr for 7-10 days Febrile neutropenia, ADULT: 1 - 2 g twice daily for septicaemia, lower most infections. For severe269 Cefepime 500 mg Injection J01DE01110P4001X A* respiratory tract infection, infections including febrile X urinary tract infection, skin neutropenia: 2 g 3 times and skin structure infections, daily. CHILD: 2 mth - 16 yr: gynaecologic and intra- ≤40 kg: 50 mg/kg every 8-12 abdominal infections hr for 7-10 days ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g270 Cefoperazone Sodium 1 g J01DD12520P4002X A Infections due to gram- daily in divided doses. CHILD Injection X negative bacteria & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may271 Cefoperazone Sodium 2 g J01DD12520P4003X A Infections due to gram- be doubled. Maximum: 16 g Injection X negative bacteria daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less thanUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 45 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 8 days: 50 - 200 mg/kg/day 12 hourly ADULT: 1 - 2 g twice daily. In severe or refractory infections the daily dosage of i) Treatment of infections due sulbactam/cefoperazone may to multi-drug resistance be increased up to 8g (4g Cefoperazone Sodium 500 J01DD62000P4001X A pathogens producing B- cefopreazone activity)272 mg & Sulbactam Sodium X lactamase CHILD: 40 - 80 mg/kg/day in ii) Treatment of infections 2 to 4 equally divided doses; 500 mg Injection caused by Acinetobacter in serious or refractory species infections, may increase to 160mg/kg/d in 2 - 4 equally divided doses. ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g273 Cefoperazone Sodium 500 J01DD12520P4001X A Infections due to gram- daily in divided doses. CHILD mg Injection X negative bacteria & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly ADULT: 1 g 12 hourly (up to274 Cefotaxime 1 g Injection J01DD01520P4002X A Infections due to gram- 12 g/day in severe cases). X negative bacteria CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses ADULT: 1 g 12 hourly (up to Cefotaxime 500 mg J01DD01520P4001X Infections due to gram- 12 g/day in severe cases).275 Injection X A negative bacteria CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses276 Ceftaroline Fosamil 600mg J01D102000P4001X A* Treatment of complicated 600mg administered every Powder for concentrate for X skin and soft tissue infections 12 hours by intravenous solution for infusion (cSSTI) in adults Restriction: infusion over 60 minutes for Restricted for only 5-14 days. Dose adjustment complicated SSTI in patients in renal impairment: - CrCl > who are unable to tolerate or 30 to ≤50 ml/min : 400mg not responding to every 12 hours - CrCl < vancomycin. 30ml/min is not recommended ADULT: 1 g 8 hourly or 2 g277 Ceftazidime 1 g Injection J01DD02520P4003X A Severe gram negative 12 hourly. In severe X bacterial infections infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses ADULT: 1 g 8 hourly or 2 g278 Ceftazidime 2 g Injection J01DD02520P4004X A Severe gram negative 12 hourly. In severe X bacterial infections infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe279 Ceftazidime 250 mg J01DD02520P4001X A Severe gram negative infections: 2 g 8 hourly. Injection X bacterial infections CHILD: 25 - 150 mg/kg/day in 2 - 3 divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 46 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe280 Ceftazidime 500 mg J01DD02520P4002X A Severe gram negative infections: 2 g 8 hourly. Injection X bacterial infections CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses i) 250 mg by deep IM injection281 Ceftriaxone 0.25 g Injection J01DD04520P4001X A/KK i) Gonorrhoea ii) single IM injection 250 mg X ii) Chancroid only. For severe infection up to 100 mg/kg/day ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years:282 Ceftriaxone 0.5 g Injection J01DD04520P4002X A Infections caused by 20 - 80 mg/kg body weight X susceptible organisms daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years:283 Ceftriaxone 1g Injection J01DD04520P4003X A Infections caused by 20 - 80 mg/kg body weight X susceptible organisms daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg284 Cefuroxime Axetil 125 mg J01DC02233T1001X A/KK Upper and lower respiratory ADULT: 250 mg twice daily; Tablet X tract, genito-urinary tract, UTI: 125 mg twice daily. skin & soft tissue and urinary CHILD:30 mg/kg/day in 2 tract infections (UTI) divided doses, up to 500 mg daily285 Cefuroxime Axetil 125 mg/5 J01DC02233F2101X A Infections caused by 30 mg/kg/day in 2 divided ml Suspension X susceptible organisms doses, up to 500 mg daily.286 Cefuroxime Axetil 250 mg J01DC02233T1002X A/KK Upper and lower respiratory ADULT: 250 mg twice daily; Tablet X tract, genito-urinary tract, UTI: 125 mg twice daily. skin & soft tissue and urinary CHILD:30 mg/kg/day in 2 tract infections (UTI) divided doses, up to 500 mg daily ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe287 Cefuroxime Sodium 1.5 g J01DC02520P4003X A Infections caused by infections: 1.5 g every 6 - 8 Injection X susceptible organisms, hours as IV. CHILD: 30 - 100 surgical prophylaxis mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV288 Cefuroxime Sodium 250 mg J01DC02520P4001X A Infections caused by ADULT: 750 mg every 6 - 8 susceptible organisms, hours as IM or IV. Severe Injection X surgical prophylaxis infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 47 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY mg/kg/day in 3 - 4 divided289 Cefuroxime Sodium 750 mg J01DC02520P4002X A Infections caused by doses or 2-3 divided doses in susceptible organisms, neonates. Surgical Injection X surgical prophylaxis prophylaxis: 1.5 g IV i) Osteoarthritis ii) ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe290 Celecoxib 200 mg Capsule M01AH01000C1001 A Rheumatoid Arthritis iii) infections: 1.5 g every 6 - 8 XX Acute pain iv) Ankylosing hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided Spondylitis doses or 2-3 divided doses in neonates. Surgical i) Osteoarthritis prophylaxis: 1.5 g IV i) ADULTS: 200 mg once291 Celecoxib 400 mg Capsule M01AH01000C1002 A* ii) Rheumatoid Arthritis daily. May increase to 200 XX iii) Acute pain iv) Ankylosing mg bid, if necessary. CHILD Spondylitis not recommended ii) 100mg twice daily, increased if292 Cephalexin Monohydrate J01DB01010F2101X B Respiratory tract infections, necessary to 200 mg 2 times 125 mg/5 ml Syrup X ear, nose and throat daily; CHILD not infections, urinary tract recommended iii) 400mg as a single dose on first day followed by 200mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment i) ADULTS: 200 mg once daily. CHILD not recommended ii) 100 mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400 mg as a single dose on first day followed by 200 mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment CHILD: 25 - 100 mg/kg/day every 6 hourly. Maximum: 4 g dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 48 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY infections, obstetric and gynaecologic infections i) 250 mg 6 hourly i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly urinary tract infection iii) 1 - 1.5 g 3 times daily or 4293 Cephalexin Monohydrate J01DB01010C1001X B ii) Complicated, recurrent or times daily. Maximum: 6 250 mg Capsule X chronic infections, bronchitis g/day Child: 25-100 mg/kg iii) Pneumonia daily in divided doses. Max: 4 g daily. i) 250 mg 6 hourly i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly294 Cephalexin Monohydrate J01DB01010T1001X B urinary tract infection iii) 1 - 1.5 g 3 times daily or 4 250 mg Tablet X ii) Complicated, recurrent or times daily. Maximum: 6 chronic infections, bronchitis g/day Child: 25-100 mg/kg iii) Pneumonia daily in divided doses. Max: 4 g daily. i) 250 mg 6 hourly i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly urinary tract infection iii) 1 - 1.5 g 3 times daily or 4295 Cephalexin Monohydrate J01DB01010C1002X B ii) Complicated, recurrent or times daily. Maximum: 6 500 mg Capsule X chronic infections, bronchitis g/day Child: 25-100 mg/kg iii) Pneumonia daily in divided doses. Max: 4 g daily. i) 250 mg 6 hourly i) Respiratory tract infection, ii) 250 - 500 mg 6 hourly296 Cephalexin Monohydrate J01DB01010T1002X B urinary tract infection iii) 1 - 1.5 g 3 times daily or 4 500 mg Tablet X ii) Complicated, recurrent or times daily. Maximum: 6 chronic infections, bronchitis g/day Child: 25-100 mg/kg iii) Pneumonia daily in divided doses. Max: 4 g daily.297 Cetirizine HCl 10 mg Tablet R06AE07110T1001X A/KK Urticaria, allergic dermatoses ADULT and CHILD over 6 X (insect bites, atopic eczema), years: 10 mg daily or 5 mg perennial rhinitis, allergic twice daily. Child 2-6 years: 5 rhinitis mg once daily or 2.5 mg twice daily298 Cetrimide 1-2% Lotion. D08AJ04000L6001X C+ As shampoo and cleansing Apply to affected area X agent Prevention of premature Given by SC 0.25 mg/day, ovulation in patients given either in the morning undergoing a controlled beginning on the day 5 or 6 H01CC02122P4001299 Cetrorelix 0.25 mg Injection XX A* ovarian stimulation, followed of ovarian stimulation or in by oocyte pick-up and the evening beginning on day assisted reproductive 5, and continued until techniques ovulation induction300 Cetuximab 5 mg/ml Solution L01XC06000P5002X A* For neo-adjuvant treatment Administered once a week. for Infusion X of KRAS wild type metastatic The very first dose is 400mg colorectal cancer with the cetuximab per m2 body aim of liver resection with the surface area with a following conditions: recommended infusion i) The primary colorectal period of 120 minutes. All tumour has been resected or subsequent weekly doses is potentially resected. are 250mg per m2 body ii) The metastatic disease is surface area each with a confined to the liver and is recommended infusion unresectable period of 60 minutes. The iii) The patient is fit enough toUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 49 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY undergo surgery to resect the maximum infusion rate must primary colorectal tumour not exceed 10mg/min. and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. iv)The treatment is limited to 16 weeks i) ADULT 0.5-1 g given 3-4 times daily. CHILD half adult dose. ii) Need to be dissolved in liquid (slurry consistency). ADULT and CHILD over 12 years: initial 30-100 g or 1-2 i) Diarrhoea and food g/kg; repeat initial dose as poisoning soon as possible or 20-50 g Charcoal, Activated 250 mg A07BA01000T1001X ii) Reduce absorption of every 2-6 hours. CHILD over301 Tablet X C drugs, plant, inorganic poison 1-12 years, 25-50 g or 1-2 and chemicals in poisoning g/kg; may repeat half the cases initial dose every 2-6 hour as needed. CHILD to 1 year of age, 1 g/kg; may repeat half the initial dose every 2-6 hours as needed. For maximum efficacy administer within 1 hour after ingestion of toxic compound ADULT: Acute poisoning: 50302 Charcoal, Activated 50 g A07BA01000F1001X A Emergency treatment of - 100g in suspension. Severe Granules X acute oral poisoning and poisoning: 50 - 100g as an drug overdose initial dose followed by 20g every 4 - 6 hours. CHILDREN: 1g/kg/dose ADULT: 0.5 - 1 g (max 2 g) with plenty of water at bedtime. CHILD: Neonate: 30-50 mg/kg; up to 100 mg/kg may be used with respiratory monitoring. 1 mth-303 Chloral Hydrate 200 mg/5 N05CC01010L2101X B Preoperative sedation 12 yr: 30-50 mg/kg (max: 1 ml Mixture X g); up to 100 mg/kg (max: 2 g) may be used; 12-18 yr: 1-2 g. Doses to be taken 45-60 minutes before procedure. May be given rectally if oral route is not available. General: Initial: 0.1 -0.2 mg/kg body weight daily for 4 - 8 weeks maintanance: given either by reduced daily304 Chlorambucil 2 mg Tablet L01AA02000T1001X A Low grade lymphoma, dosage or intermittent course X chronic lymphocytic of treatment. Chronic leukaemia. Ovarian cancer Lymphocytic Leukaemia: initial : 0.15mg/kg/day untill total leukocyte count has fallen to 10,000peruL, thenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 50 / 314